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ABSTRACT
IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF
FUNCTIONAL MOTIFS IN THE PORPHYROMONAS GINGIVALIS
MFA1 SHORT FIMBRIA
By
Mohammad K. Roky
23rd July, 2020

Porphyromonas gingivalis is a causative agent of periodontal disease, initially colonizes
the oral cavity by adhering to commensal streptococci. Adherence requires the interaction
of the minor fimbrial protein (Mfa1) of P. gingivalis with streptococcal antigen I/II (Ag
I/II). A peptide derived from Ag I/II peptide has been well characterized and shown to
significantly reduce P. gingivalis colonization and bone loss in vivo, suggesting that this
interaction represents a potential target for therapeutic intervention. However, the
functional motifs of Mfa1 involved in the interaction with Ag I/II remain
uncharacterized. A series of N- and C-terminal peptide fragments of Mfa1 were
expressed and tested for inhibition of P. gingivalis adherence to S. gordonii. Residues
225-400 of Mfa1 was identified as essential for P. gingivalis adherence. Using the threev

dimensional structure of Mfa1, a putative binding cleft was identified and five smallmolecule peptidomimetics based on the AgI/II peptide could be docked in this site. Site‐
specific mutation of amino acids in the predicted cleft, specifically, R240A, W275A,
D321A and A357P inhibited the interaction of Mfa1 with streptococci. Additionally,
complementation of an Mfa1‐deficient P. gingivalis strain with wild‐type mfa1 restored
adherence to streptococci, whereas complementation with the site‐specific mfa1 mutants
resulted in significantly reduced levels of adherence.

To develop targeted small molecule inhibitors of this protein-protein interaction, virtual
screening was performed to identify compounds that exhibit structural similarity with the
two

functional

motifs

(NITVK

and

VQDLL)

of

the AgI/II

peptide. Thirty-

three compounds were tested for in vitro inhibition of P. gingivalis adherence, and the
three most potent compounds, N7, N17 and V8, were further characterized. In vivo
efficacy of these compounds was evaluated in a murine model of periodontitis. Treatment
of mice with each of the compounds reduced P. gingivalis-mediated gingival
inflammation as determined by IL-17 expression and significantly reduced maxillary
alveolar bone resorption in infected animals. Finally, a series of cytotoxicity tests were
performed with human and murine cell lines. N17 and V8 did not show any cytotoxic
activity. In summary, we successfully characterized the Mfa1 binding site and identified
compounds N17 and V8 as potential lead compounds that will provide the platform to
design more potent therapeutic agents that may function to limit or prevent
P. gingivalis colonization of the oral cavity.
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CHAPTER ONE: INTRODUCTION
Periodontal disease: The ancient Chinese and Egyptians described the periodontal
disease as an inflammatory condition over 4000 years ago and Hippocrates (400-335 BC)
defined the disease as "the gums were bleeding or rotten" [1, 2]. Since then, periodontal
diseases have been considered to be a group of chronic inflammatory conditions of the
gingiva (soft tissues surrounding the teeth) and tissues supporting the teeth (collagen
fiber) caused by dental plaque or a microbial biofilm. This disease represents a significant
oral health concern and is a substantial contributor to tooth loss [3] and if not treated
properly could even lead to death [4]. The early stage of periodontal disease is gingivitis
which is manifest by localized inflammation of gingival tissue, characterized by redness,
swollen and tender gums or that readily bleed upon probing. If the infection persists,
disease can advance to chronic irreversible inflammation that leads to the destruction of
alveolar bone and ligament, resulting in attachment loss that increases the depth of the
periodontal pockets, which is a hallmark symptom of advanced periodontal disease.
Epidemiology of Periodontal Disease: According to Tonetti et al., periodontal disease is
the most prevalent disease in humankind [5]. The global burden of disease study from
1990 to 2010 ranked periodontal disease as the sixth most pervasive disease in the world
that affects 11.4% or 743 million people worldwide [6, 7] and 158 million people face
consequences of tooth loss, especially older adults [6]. The World Health Organization
(WHO) maintains an oral health database that collects data from different countries based
1

on the Community Periodontal Index (CPI)[8]. The CPI score is an indication of the
severity of periodontal disease in the community and ranges from 0 to 4. As attachment
loss and probing depth (PD) are considered to be the gold standard for the prevalence of
the periodontal disease [9], a CPI score of 0 indicates no periodontal disease, a score of 1
indicates bleeding on probing; 2 indicates the presence of calculus and bleeding; 3 is
associated with subgingival pocket depths 4-5 mm and 4 represents very deep
subgingival pockets of 6 mm or greater. Based on these criteria, studies indicate that 35%
to 70% of adolescents in developing nations have calculus deposits whereas only 4% to
34% exhibit calculus in developed countries. In the adult population, 36-63% exhibit
calculus deposition in developing nations and 14-47% in developed nations [8]. In the
US, 42% of the adult population at 30 years of age or older suffer from periodontitis and
7.8% of this adult group have severe periodontitis. Severe periodontitis is mostly
prevalent in adults 65 years or older, and in Mexican American, non-Hispanic black
populations, and in smokers [10].
Risk factors of periodontal disease: Some of the risk factors of periodontal disease are
modifiable, and some are non modifiable. Smoking is the major modifiable risk factor of
periodontal disease, and the smokers suffer three times greater risk of severe periodontitis
than the non-smoker [11]. The initiation and progression of periodontitis in smokers is
more rapid and show these individuals show inferior treatment outcomes compare to nonsmokers [11-13]. Diabetes mellitus is the most notable systemic disease considered as a
risk factor for the onset of periodontal disease both in young people and adults. It
contributes to periodontal disease by exerting an enhanced inflammatory response
relative to non-diabetic patients [14-16]. Globally, socioeconomic conditions also play a
2

vital role in periodontal disease due to the higher cost of treatments [6, 17]. For example
in the United States, severe periodontitis is most common in Mexican American and
African American populations who live under the federal poverty line [9, 10, 18]. Other
factors such as stress and increased insulin resistance also represent potential risk factors
for periodontal disease [19, 20]. This anger, job-related stress, or the stress associated
with military service can predispose individuals to periodontal disease [21-23].
Age and heredity are some of the non modifiable risk factors. All of the systemic reviews
have consistently shown the adults aged 60-69 years are more prone to periodontal
disease than the 40-50 years age group

[10, 24]. Although no single nucleotide

polymorphisms related to genetic predisposition to periodontal disease have been
identified, people with different genetic backgrounds and associated with various
environmental factors can be more prone to this disease [23, 25].
Association of periodontal disease with systemic disease: Around 1891, W. D. Millar
first advanced the notion of the relationship between oral and systemic infection [26]. In
1900, a British doctor, William Hunter, proposed the focal infection hypothesis and
suggested that the extraction of the teeth alleviates the disease burden and improves the
overall health in patients [26, 27]. In the 1980s, the association of periodontal disease
and systemic disease became more apparent as a well-defined study observed that
myocardial infraction was associated with poor oral health [28]. Since then, the number
of studies have explored the association between oral health and other systemic diseases
such as atherosclerotic cardiovascular disease [29], diabetes [16]
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, adverse pregnancy outcome [30], respiratory disease [31, 32], chronic kidney disease
[33], rheumatoid arthritis [34], cognitive impairment [35], obesity [36], metabolic
syndrome [37] and cancer [38]. The link between periodontal disease and other systemic
diseases is bidirectional and exact mechanisms to explain these associations have yet to
be defined. However, one possible mechanism may be the direct involvement of oral
pathogens in systemic disease progression and oral pathogens have been detected in
thrombi from patients with acute myocardial infarction [39]. In addition, an indirect
mechanism may involve the secretion of inflammatory factors, such as C reactive protein
which is elevated during chronic periodontitis into the bloodstream [40].
Pathophysiology of periodontal disease: Periodontal disease is defined as a
polymicrobial

community-mediated

chronic

inflammatory disease

and

chronic

inflammation in the host leads to the destruction of alveolar bone and subsequent sulcus
formation [41-43]. The microbes that reside in the oral cavity comprise hundreds of
species of different bacteria, fungi, and viruses [44, 45]. These organisms adhere to solid
surfaces (e.g., the tooth surface or metal implants) and form a highly organized biofilm
structure [46]. The simple depiction of organized microbial communities in oral biofilm
represented by the Figure 1.1. The initial stage of biofilm formation is the adsorption of
salivary macromolecules (mucin, proteins) on the enamel surface to generate the acquired
pellicle. Gram-positive organisms such as Actinomyces and Streptococcus species
represent primary colonizers, as these bacteria can readily adhere to this acquired pellicle
through species-specific receptor-ligand interactions [47]. Once attached, these bacteria
promote further increases in biofilm biomass through co-aggregation interactions and
initiate the generation of an extracellular matrix, which also promotes the adhesion of
4

other bacteria. As the biofilm biomass and thickness increases, the consumption and
diffusion of oxygen and other nutrients promotes the generation of anaerobic
environments that facilitates the enrichment of the later colonizing pathogenic Gramnegative flora, including red-complex bacteria Porphyromonas gingivalis, Tannerella
forsythia, and Treponema denticola [48]. In many cases, the attachment of Gramnegative organisms to the Gram-positive colonizers is mediated by specific sets of
adhesin-receptor interactions. Interspecies cell signaling, metabolic cross-feeding,
synergistic cooperation and interspecies antagonism can each contribute to the
establishment of this polymicrobial community [49-51]. Finally, calcification of this
biofilm occurs through the deposition of calcium and phosphate ions from serum (in
subgingival biofilm) or from the saliva (in supragingival biofilm) to form the mature
dental plaque or calculus [19, 23]. In a healthy individual, the host-microbe homeostasis
is important for maintaining oral health. However, disrupting homeostasis and changing
the overall microbial composition of the dental biofilm, especially by the Gram-negative
bacterium P. gingivalis, can create a dysbiotic microbiota which can elicit uncontrolled
inflammation leading to permanent tissue damage [52-54].
Both innate and adaptive immunity is involved in controlling the formation of dental
plaque. Epithelial cells are the first-line of host defense and act as a physical barrier but
in response to microbial metabolites can secrete cytokines and stimulate neurons to
produce neuropeptides that increase blood flow in the local tissue [55]. Dendritic
Langerhans cells uptake microbial antigens and present the antigen to the lymph node to
promote the infiltration of neutrophils, granulocytes, and lymphocytes. Neutrophils
phagocytose bacteria and contribute to maintaining homeostasis between oral microbes
5

and the host. However, a dysbiotic microbiota leads to the hyperactivation of neutrophils
that increases the production of enzymatic activity and reactive oxygen species leading to
tissue damage. For example, the increased level of myeloperoxidase produced by
hyperactive neutrophils impairs the balance of membrane metalloproteinases,

thus

eventually leading to bone resorption by the degradation of ligament fibers by
metalloproteinases [56]. Most of the B cells that reach the site of infection represent
sIgA antibody-producing plasma cells, which may also play a role in controlling the
microbial growth [57]. However, plasma cells also produce various cytokines such as
TNFα, IL-6, IL-10, TGFβ and metalloproteinases, which can contribute to tissue
destruction [58]. Additionally, T cell-mediated immune response occurs through
stimulation of Th1, Th2, and Th17 subsets as well as various Treg populations [55].

6

Figure 1.1. Simplified depiction of dental plaque biofilm: Dental biofilm is highly
organized microbial structure started with acquired pellicle formation where early
colonizer readily adhere and provide the substrata for late colonizer. Blue line indicate
adhesin receptor interaction among microbes, also metabolic cross talk common event in
dental biofilm. Image is modified from Wright et al. 2013 [59].
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P. gingivalis:

P. gingivalis is a Gram-negative rod-shaped, asaccharoytic, obligate

anaerobic bacterium that produces a number of virulence factors. Most notable are the
Arg- and Lys-specific gingipains that degrade host proteins, including complement
system activation proteins. In addition, a serine phosphatase (SerB) can suppress IL-8
production, and lipid A1-4 phosphatase can function to modify lipid A to subvert host
immune response. Nucleoside diphosphate kinase suppresses ATP induced cell apoptosis
and P. gingivalis fimbriae mediate the colonization and interbacterial adhesion as well as
contribute to immunosuppression [51, 60]. Although periodontal disease is caused by a
polymicrobial infection, P. gingivalis is considered to be a vital contributor to disease
onset and progression. P. gingivalis is detected in 85% of the disease cases [61], strongly
correlates with subgingival pocket depth [62] and has been shown to induce alveolar
bone loss in an animal model [52, 63].
The primary niche of P. gingivalis is the subgingival area of the teeth, where conditions
are optimal for the successful colonization and growth of the obligate anaerobic bacteria
[64]. However, to colonize this preferred niche, P. gingivalis must first overcome
obstacles in the supragingival environment such as the mechanical shearing forces that
arise from tongue movement or the flow of saliva and gingival crevicular fluid.
Furthermore, specific salivary molecules can promote microbial clearance via
expectoration or swallowing [65]. To survive in this hostile environment, P. gingivalis
adheres to other bacterial species that exist in the supragingival microbiota [66-68]. Coadhesion of P. gingivalis with other bacteria is mediated by specific set of adhesinreceptor interactions and may be driven by physiologic compatibility of the adherent
organisms. For instance, Fusobacterium nucleatum co-aggregates with P. gingivalis and
8

supports the growth of P. gingivalis by reducing oxygen levels to that which can be
tolerated by P. gingivalis [66]. F. nucleatum can also generate ammonia from salivary
aspartate and glutamate, which raises the pH level, supporting the growth of acid
intolerant P. gingivalis [69]. Similarly, P. gingivalis can adhere to the oral streptococci,
specifically to streptococci of the oralis, sanguinis, and mitis groups but not to
Streptococcus mutans [67, 70, 71]. The physiological basis for this species-specific
interaction might arise from the acidophilic nature of the mutans group in contrast to
other streptococcal groups. Moreover, the introduction of P. gingivalis in human
volunteers showed P. gingivalis localized exclusively in the supragingival biofilm where
streptococcal species predominate [72]. Furthermore, S. gordonii secretes the folate
synthesis precursor para-aminobenzoic acid (PABA), which is essential for histidine
metabolism in P. gingivalis and thus may support the growth of this organism in
supragingival biofilm [51]. Thus, P. gingivalis may initially colonize the oral cavity by
interacting with streptococci in supragingival biofilm as a precursor to becoming
established in its preferred niche in the subgingival biofilm.
P. gingivalis fimbriae: P. gingivalis express two distinct types of fimbriae in its surface
that participate in nearly all host-pathogen interactions as well as bacterial co-adhesion
with biofilm microbiota [73]. The fimbrial subunit of long fimbriae is FimA encoded by
the fimA gene [74] which exists in six sub-families designated as genotypes I to VI [7375].

However, FimA genotype II is the most common in P. gingivalis, and both

genotypes II and IV have been suggested to be more virulent than the other groups [7678]. Other accessory proteins that comprise the FimA fimbriae are encoded by the
fimABCDE operon. FimB localizes in the outer membrane, and facilitates anchoring and
9

the regulation of expression and length of FimA [79]. FimC, FimD, and FimE are
accessory proteins that mainly contribute to tip formation and may be involved in the
adhesive functions of the FimA fimbriae [80, 81]. FimA fimbriae play a crucial role in
the pathogenesis of P. gingivalis as they mediate interaction with the 51-integrin
family of proteins facilitate the endocytosis of this organism in phagocytic cells by actin
cytoskeletal remodeling and once inside the host cells, P. gingivalis impairs phagocytic
killing mechanisms [82].

FimA has also been suggested to be involved in the

pathogenesis of rheumatoid arthritis since it mediates the initial invasion of osteoblasts
[83, 84]. In addition, FimA mediates co-aggregation and microcolony formation with
other bacterial communities in the oral biofilm. For example, FimA mediates adhesion to
Actinomyces

viscosus [85], Treponema

denticola [86], Streptococcus

gordonii [87],

and Streptococcus oralis [88] via specific adhesin receptor interactions and also binds to
dentilisin of T. denticola and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of S.
gordonii and S. oralis [51].
The short or minor fimbriae of P. gingivalis are comprised of the structural protein Mfa1
and are antigenically distinct from the long fimbriae (FimA). However, a recent study
indicates that FimA and Mfa1 are structurally related and contain a conserved fold [89].
Mfa1 is encoded by the mfa1 co-expressed with the other accessory proteins Mfa2, Mfa3,
Mfa4, and Mfa5 (Figure 1.2a). Mfa2 functions to anchor the fimbriae and regulate
fimbrial length, similar to the function of FimB. Mfa3, Mfa4, Mfa5 correspond to long
fimbrial components FimC, FimD, and FimE, and may be involved in tip formation and
essential for the adhesive function of minor fimbriae [82, 90]. Mfa1 also interacts with
DC-SIGN (dendritic cell-specific ICAM-3 grabbing nonintegrin) of dendritic cells [91]
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and induces secretion of inflammatory cytokines such as IL-1β, IL-8, IL-6, and TNFα
[91, 92]. Minor fimbriae also stimulate the production of interleukin-1α (IL-1α), IL-1β,
IL-6, and tumor necrosis factor-α (TNF-α) by macrophages and has been suggested to be
a causative factor of alveolar bone resorption in animal models [78, 93].

A major

function of the minor fimbriae involve the co-aggregation of P. gingivalis with specific
streptococcal species. Park et al. showed that Mfa1 is required for community formation
with S. gordonii, and interacts with the S gordonii surface antigen Ag I/II [94]. Minor
fimbriae also involved in P. gingivalis autoaggregation, monospecies microcolony
formation, and mature biofilm formation [95].
Recent studies indicate that the biogenesis of Mfa1 and FimA fimbriae most likely occur
through a donor strand based exchange mechanism (DSE) observed in type I and P
fimbriae assembly in E. coli but no chaperone-usher pathway is involved in P. gingival
fimbrial biogenesis [89, 96-101]. Mfa1 and FimA fimbriae are both synthesized as preproproteins

(Figure 1.2b) containing an N-terminal signal peptide that mediates

translocation of the proteins across the inner membrane into periplasmic space. Upon
translocation, the signal peptide is removed by signal peptidase and the proproteins
become lipidated [102, 103]. The proproteins are secreted across the outer membrane and
are anchored on the membrane most likely by the lipid moiety. Each protein then
undergoes further proteolytic cleavage by Rgp to produce the mature structural subunits
of the respective fimbriae [103, 104]. Cleavage by Rgp results in the formation of a long
hydrophobic motif that subsequently interacts with a β-strand from the adjacent subunit
of the growing fibril (Figure 1.2c) [89]. Mfa2 act as an anchor protein that anchor the
Mfa1 fimbriae in the outer membrane and also act as an elongation and assembly
11

terminator [105]. Finally, Mfa3, Mfa4 and Mfa5 accessory protein assembled in the distal
part of the mature fimbriae [106, 107].
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Mfa1

A)

B)

B)

Pre-pro
peptide

Mfa2

Mfa3

Signal peptide N-terminal extension
subunit

Mfa4

Mfa5

Mfa1 monomeric

Pro-peptide

C)

Figure 1.2. Mfa1 polymerization: A) The anchor protein Mfa2 along with tip protein
Mfa3, Mfa4 and Mfa5 coexpressed with Mfa1. B) Mfa1 expressed as pre-pro peptide, the
signal peptide remove by peptidase where the N terminal extension further removed by
Rgp in the cell surface to produce mature Mfa1 monomer. C)The proposed donor strand
exchange mechanism of type V fimbria assembly by Xu et al. [89].
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Oral streptococci: The oral streptococci are Gram-positive, facultative bacteria that
constitute the majority of the cultivatable bacterial community in dental plaque [47, 108,
109] and are considered to be beneficial to oral health [110]. Oral streptococci promote
the colonization and growth of other commensals such as Actinomyces spp and
Veillonella spp and may antagonize the colonization by pathogenic organisms [111]. The
presence of beneficial streptococci such as S. gordonii, S. sanguinis, and S. parasanguinis
is associated with protection against cariogenic S. mutans pathogenesis [112].
Streptococcus mutans is notable for its ability to ferment pyruvic acid to lactic acid
resulting in decreased pH levels (below 5.5) that promotes demineralization of enamel
and dentin, contributing to cavity formation [113]. In contrast, the commensal
streptococci produce ammonia by the arginine deaminase system (ads) [114]. Commensal
streptococci also generate H2O2 which prevents colonization of S. mutans as well as
downregulates bacteriocin expression by interfering with the S. mutans quorum-sensing
system [115-118]. Other oral streptococci, such as S. cristatus downregulate FimA
expression in P. gingivalis, which may interfere with P. gingivalis colonization of the
subgingival biofilm [118, 119]. However, recent studies indicate that the beneficial role
of the oral streptococci may be questionable since they also contribute to the
development of pathogenic dental biofilm. For instance, S gordonii, along with the F.
nucleatum, may reduce the oxygen concentration to levels which can be tolerated by P.
gingivalis, resulting in P. gingivalis colonization [120]. A. actinomycetemcomitans, the
predominant pathogen in localized aggressive periodontitis (LAP) can metabolize lactate
produced by S. gordonii, an end product of the fermentation of low molecular weight
carbohydrates,

thus

support

the

growth
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and

enhance

the

virulence

of

A.

actinomycetemcomitans [121, 122]. S. gordonii also enhances Candida albicans hyphal
formation and promotes community formation in the oral cavity [123].
Streptococcal adhesins: Oral streptoccoci possess a plethora of adhesin molecules that
facilitate the colonization of the tooth surface via interaction with the acquired pellicle,
epithelial cell interactions and coaggregation with other organisms such as F. nucleatum,
P. gingivalis and A. actinomycetemcomitans [110]. The most prominent adhesins of oral
streptococci are the antigen I/II family of adhesins (e.g., SpaP, P1, PAc, SspA, SspB)
that are expressed by many if not all species of oral streptococci [124]. The primary
sequences of Ag I/II proteins highlight distinct features of their structure, including a
signal peptide (residues 1-38), an Alanine rich N-terminal repeat domain (residues 164471), a divergent domain (residues 472-770), a Proline repeat domain (residues 771-887),
a highly conserved C-terminal region (residues 888-1413) and a sorting sequence
(LPXTG) and transmembrane domain (residues 1537-1556) [125]. These proteins
mediate streptococcal binding to the salivary glycoprotein gp340 (DMBT1), speciesspecific community formation with P. gingivalis and coaggregation with Actinomyces
and C. albicans [70, 125, 126]. S. gordonii expresses two paralogs of AgI/II (SspA and
SspB) which are distinct from Ag I/II of S. mutans

[87, 127]. Among other notable

adhesins of streptococci is the serine rich repeat glycoprotein (srr) involved in binding to
sialylated glycans of the soluble human salivary mucin [112, 128] and with platelet
glycoproteins [129]. GAPDH, a glycolytic enzyme found on the streptococcal surface can
bind to fibronectin, lysozyme, as well as other proteins related to cytoskeletal
rearrangement [130]. CshA and CshB, fibrillar proteins expressed by many oral
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streptococci also bind to fibronectin as well as to other organisms in the oral biofilm
[131, 132].
Community formation between P. gingivalis with oral streptococci: The adherence of
P. gingivalis to S. gordonii is multimodal and is mediated by two sets of adhesin-receptor
interactions (Figure: 1.3) [42]. P. gingivalis FimA binds to GAPDH on the streptococcal
surface and Mfa1 interacts with specific streptococcal Ag I/II proteins. The binding
region of GAPDH that interacts with FimA encompasses amino acids 166 to 183, a
region predicted to be β-sheet and likely involves hydrophobic interactions with FimA
[133]. However, this interaction alone is not sufficient to drive community formation.
Park et al. showed that community formation is driven by the interaction of Mfa1 with
Ag I/II [94] and Daep et al. showed that this interaction is essential for in vitro biofilm
formation [134] and for the pathogenesis of P. gingivalis in a murine model of
periodontitis [135]. Demuth et al. showed that SspB residues 1167 to 1192 are essential
for the interaction of S. gordonii with P. gingivalis and within this region, Asn1182 and
Val1185 were identified as crucial amino acids

[71].

Subsequently, Daep et al.

demonstrated that a synthetic peptide derived from SspB residues 1167 to 1193
(designated BAR) functioned as a potent competitive inhibitor of P. gingivalis adherence
to S gordonii in vitro, exhibiting a 50% inhibitory concentration of 1.3µM [135].
Structural dissection of BAR peptide at the molecular level using combinatorial peptide
libraries that replaced Asn1182, Thr1184, and Val1185 with each of the 19 common
amino acids showed that positively charged residues at the 1182 position and
hydrophobic residues at position 1185 improved BAR inhibitory actvity, suggesting that
this adhesin-receptor interaction requires both electrostatic and hydrophobic interactions
16

[134]. Further dissection of BAR identified a second motif in BAR that was important for
P. gingivalis adherence.

This motif

(VQDLL) forms an amphipathic α-helix and

resembles the core element of the eukaryotic nucear receptor (NR) box protein-protein
interaction domain [135, 136]. Disruption of this motif severely impairs the binding of P.
gingivalis to streptococci. Although Ag I/II has been well charecterized, the binding
region of Mfa1 remains to be characterized.
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P. gingivalis

Mfa1

FimA

1167-LEAAPKKVQDLLKKANITVKGAFQLFS
-1193

GAPDH

SspA/B

S. gordonii

Figure 1.3. Multimodal interaction of P. gingivalis with S. gordonii: Long fimbriae
FimA of P. gingivalis interacts with GAPDH of S. gordonii, whereas short or minor
fimbriae Mfa1 interacts with SspA/B surface antigen. Binding region of SspA/B
encompasses 1167-1193 amino acid residues comprised of VQDLL and NITVK motifs
(red, underlined).
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Development of targeted therapeutics for treatment of periodontal disease: Nonsurgical treatment of periodontal disease consists of professional debridement of both
supragingival and subgingival plaque and calculus with scaling and root planing. In
conjunction with nonsurgical treatment, antibiotic therapy of several broad-spectrum
antibiotics can significantly improve gum health [137, 138]. However, this approach is
inefficient when the subgingival pocket depth is >6 mm. For these cases, a surgical
procedure such as open flap debridement is required to separate the gingival tissue from
the underlying tissue in order to access the plaque and reduce subgingival pocket depth
[139, 140]. In general, these approaches have limitations. For instance, treatment with
broad-spectrum antibiotics indiscriminately kills the oral microbiome, including
commensal bacteria and concern is growing over the development of antibiotic
resistance. The surgical procedures are invasive and expensive and disease often recurs.
Thus, there is a need to develop novel therapeutic approaches for the targeted (e.g.,
species specific) elimination of pathogenic bacteria. To develop targeted therapy against
P. gingivalis, Deap et. al. tested the efficacy of synthetic BAR peptide (SspB adherent
region) in mouse model of periodontitis and demonstrated peptide-mediated inhibiton of
P. gingivalis virulence [135]. Patil et. al synthesized small molecule peptidomimetics
based on BAR that showed promising activity in the reduction of in vitro P. gingivalis
biofilm formation with S. gordonii [141]. Subsequently, Tan et al. showed that these
peptidomimetics prevent colonization of P. gingivalis and reduce virulence in the mouse
model of infection [142]. However, additional structural information is required to better
understand the Mfa1/SspB interaction in order to develop and design more potent
inhibitors for species-specific novel therapy against P. gingivalis infections.
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The studies in this dissertation successfully identified and characterized the binding cleft
of Mfa1 that interacts with AgI/II and we showed that it is comprised in part of amino
acids R240, W275 and alpha-helical residues 321-328 and 351-367. Furthermore, two
small molecule inhibitors, N17 and V8, were identified that block the Mfa1/AgI/II
protein-protein interaction. These compounds reduced adherence of P. gingivalis to
streptococci in vitro and prevented P. gingivalis-mediated bone resorption in a murine
model of periodontitis. Structural information obtained from characterizing the binding
cleft of Mfa1 and the identification of lead compounds will facilitate a better
understanding of this protein-protein interaction. In turn, this information will lead to
further modification and optimization of the lead compounds to generate more potent P.
gingivalis species-specific therapeutic agents to control periodontal diseases.
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CHAPTER TWO: METHODS AND MATERIALS

2.1. Bacterial strains and growth conditions.
The strains and plasmids used in this study are shown in Table 2.1 and Table 2.2. P.
gingivalis ATCC 33277 was grown in TSBY medium comprised of trypticase soy broth
(Difco) supplemented with 2% yeast extract, 1 µg/ml hemin and 5 µg/ml menadione. For
growth on plates, this medium was further supplemented with 1.5% agar and 5% sheep
blood. The Mfa1‐deficient and complemented strains were cultured in medium
containing the appropriate antibiotics, that is, 1 and 5 µg/ml of tetracycline and
erythromycin, respectively. All P. gingivalis cultures were incubated under anaerobic
conditions (10% CO2, 10% H2 and 80% N2). Brain heart infusion agar (Difco)
supplemented with 5% yeast extract was used to grow S. gordonii DL‐1. E. coli strains
were maintained in LB medium supplemented with the appropriate antibiotic. Where
necessary, the final concentration of ampicillin was 100 µg/ml. All bacterial stocks were
stored at −80°C in the appropriate medium supplemented with 30% glycerol.
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Table 2.1. Bacterial Strain used in this study
Strain or Plasmid
S. gordonii
DL1
P.
33277
gingivalis
Smfa1

Csmfa1
Csmfa1 R240A

Csmfa1 A357P

E coli

Characteristic

ATCC
Derivative of 33277 with
insertional inactivation of
the mfa1 gene; Emr
SMF1 containing pTCOW-Mfa1,
complemented strain; Emr Tcr
Smfa1 containing pTCOW-Mfa1
with the R240A mutation,
complemented strain; Emr Tcr
SMF1 containing pTCOW-Mfa1
with mutation the A357P
mutation, complemented strain;
Emr Tcr

XL1 blue cells
BL21(DE3)pLysS

Source
reference
Lab
stock[143]
[127]

[94]
This study

This study

Agilent
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Table 2.2. Plasmid used in this study
Plasmid

pGEX6p1
pG-Mfa1
pG-N194
pG-N225
pG-N279
pG-N400
pG-C280
pT-COW
pTCOW-Mfa1

pTCOW-Mfa1
R240A
pTCOW-Mfa1
A357P

GST tag expression vector
pGEX6p1 containing mfa1(21-563aa
residues)
pGEX6p1 containing n terminal
truncated mfa1(21-194aa residues)
pGEX6p1 containing n terminal
truncated mfa1(21-225aa residues)
pGEX6p1 containing n terminal
truncated mfa1(21-279aa residues)
pGEX6p1 containing n terminal
truncated mfa1(21-400aa residues)
pGEX6p1 containing n terminal
truncated mfa1(280-563aa residues)
Shuttle vector plasmid; Amr Tcr in E.
coli; Tcr in P. gingivalis Mob+Rep+
pT-COW containing a 2.5-kb fragment
containing the upstream and coding
region of the mfa1 gene
pT-MFA containing the R240A
mutation
pT-MFA containing the A257P mutation
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This
study
This
study
This
study
This
study
This
study
This
study
[144]
[94]

This
study
This
study

2.2. Recombinant protein/peptide constructs.
Nucleotide primers used in this study are shown in Table 2.2. To generate the full‐length
Mfa1 construct lacking the signal sequence, the mfa1 sequence from 61 bp to 1689 bp
was amplified using the forward and reverse primers listed in Tablec2.3. from P.
gingivalis ATCC33277 genomic DNA using platinum PCR supermix (Invitrogen)
according to the manufacturer's instructions. Briefly, initial denaturation was carried out
at 94°C for 3 min. This was followed by 30 cycles comprised of denaturation at 94°C for
30 s, primer annealing at 55°C for 30 s and strand extension at 72°C for 90 s. The
amplified products were subsequently digested with SalI and XhoI, ligated into the
pGEX6p‐1 expression vector and transformed into chemically component E. coli BL21.
For the construction of the Mfa1 N‐terminal and C‐terminal peptide fragments N194,
N225, N279, N400 and C280, mfa1 gene fragments encoding residues 21–194, 21–225,
21–279, 21–400 and a C‐terminal fragment encoding residues 280–563 of Mfa1 were
amplified using the primers shown in Table2.2 from P. gingivalis ATCC33277 genomic
DNA. A similar approach to that described above was followed to clone these fragments
in pGEX6p1 expression vector and introduce the constructs into E. coli BL21.
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Table 2.3: Primers used in this study. Restriction enzyme sites are shown in italics.
Protein/peptide
name
Mfa1

N194

N225

N279

N400

C280
N279 R240A

N279 W275A

N400 D321A

N400 A357P

Primer sequence
FP: 5’ ATTA GTCGAC
AGTAAAGAGGGCAATGGCCCCGATCCG 3’
RP: 5’ ATGG CTCGAG TAA GAGATCAACCTCATAG 3’
FP: 5’ ATTA GTCGAC
AGTAAAGAGGGCAATGGCCCCGATCCG 3’
RP: 5’ GAAT CTCGAG TAA ACCATTCTTTTTGGCAATC
3’
FP: 5’ ATTA GTCGAC
AGTAAAGAGGGCAATGGCCCCGATCCG 3’
RP: 5’ TAAT CTC GAG TAA
CCCTGCGATAGCATTGGCCTCGGATA 3’
FP: 5’ ATTA GTCGAC
AGTAAAGAGGGCAATGGCCCCGATCCG 3’
RP: 5’ ACCT CTCGAG TAA
TTGAGCAACAACCCATCTGA 3’
FP: 5’ ATTA GTCGAC
AGTAAAGAGGGCAATGGCCCCGATCCG 3’
RP: 5’
ATTACTCGAGTTATTCTTTCTTGGGAGTAAACTTCGC
ACGAACC 3’
FP: 5’ AAAA GTCGAC GGAGAACGTCGCCAATACCT 3’
RP: 5’ ATGG CTCGAG TAA GAGATCAACCTCATAG 3’
FP: 5’ - CGT TCT GTA GCA GCT GCG ATG GTT TCA 3’
RP: 5’- CGT TGA AAC CAT CGC AGC TGC TAC AGA
ACG CTC -3’
FP: 5’- ATT ACG GAT ATC AGA GCG GTT GCT CAA
GGA -3’
RP: 5’- TCC TTG AGC AAC CGC TCT GAT ATC CGT
AAT -3’
FP: 5’ GCT ACC GAG TAT GCT TAT GCC GGT CTG
TGG 3 ’
RP: 5’ CAG ACC GGC ATA AGC ATA CTC GGT AGC
ATT TGT 3’
FP: 5’ ACT GGC GAA TTG CCA AAT GCT CTT TCA 3’
RP: 5’ TGA AAG AGC ATT TGG CAA TTC GCC AGT
CAC 3’
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2.3. Expression and purification of truncated Mfa1 peptides.
To express the full‐length and truncated Mfa1 proteins, an overnight culture containing
the desired construct was diluted in pre‐warmed LB medium supplemented with
100 µg/ml ampicillin to an OD600 nm of 0.1 and incubated at 37°C in a rotating shaker at
speed of 220 rpm. When the OD600 nm reached 0.5, protein expression was induced by
adding IPTG to a final concentration of 1mM. After further incubation for 4 hr at 37°C,
cells were harvested by centrifugation at 3,000 x g for 10 min and the cell pellets were
frozen. One gram of frozen cell pellet was suspended in 5 ml of CellLytic B (Sigma‐
Aldrich) containing lysozyme (0.2 mg/ml) and Benzonase (50 U/ml). A protease inhibitor
cocktail (Thermo Fisher Scientific) was added as per manufacturer recommendations and
incubated at 25°C for 30 min with gentle shaking. To complete the disruption of the cells,
brief sonication was carried out using a Vibra‐Cell ultrasonic Liquid Processor VCX 130
(Sonics). Cells were pulsed at 20 kHz for 2 min using a 10 s short burst followed by a
30 s cooling interval. During sonication, all steps were carried out in ice. Cell debris was
removed by centrifugation at 13,000 x g for 20 min and the supernatant was transferred to
a fresh tube.
Purification of GST‐tagged fusion proteins was carried out using the Pierce GST Spin
Purification Kit (ThermoFisher). Briefly, spin columns were equilibrated with the
equilibration/wash buffer supplied with the kit at 4°C, and then 15 ml of cell lysate
supernatant was added to each column and incubated overnight at 4°C. Columns were
washed three times with 15 ml of wash buffer by centrifugation at 700 x g for 2 min. In
column cleavage with Precision Protease (ThermoFisher) was carried out by overnight
incubation at 4°C to generate the truncated Mfa1 proteins. The Mfa1 polypeptides were
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eluted by centrifugation at 700x g for 2 min. The eluted peptides were subsequently
chromatographed in disposable PD‐10 Desalting Columns (GE Healthcare) to remove
salts. Purity of the eluted proteins was assessed using SDS‐PAGE electrophoresis and
quantification of proteins was carried out using the BCA assay (Pierce).

2.4. Dual species biofilm model.
Interspecies adherence and biofilm formation between P. gingivalis and S. gordonii were
carried out essentially as previously described [141]. S. gordonii cells were harvested
from a 10 ml of overnight culture by centrifugation at 3,000x g for 5 min, washed with
10 ml of pre‐reduced PBS (10 mM Na2HPO4, 18 mM KH2PO4, 1.37 M NaCl and 2.7 mM
KCl, pH 7.2) and suspended in 1 ml of PBS. Suspended S. gordonii cells were labeled
with 20 µl Hexidium Iodide (1.6 mg/ml; Molecular Probes, Eugene, OR) in the dark at
25°C with gentle shaking on a rocker platform for 15–30 min. Unbound dye was
removed by washing with PBS and labeled cells were then suspended in 1 ml of pre‐
reduced PBS. Cells were diluted to O.D.600nm of 0.8 and 1 ml of the labeled cells was
added to each well of a 12‐well microtiter plate (Greiner Bio‐one) containing a circular
glass coverslip. Plates were incubated for 24 hr on a rotary shaker under anaerobic
conditions. The following day, P. gingivalis cells were harvested from 10 ml of overnight
culture, suspended in 1 ml pre‐reduced PBS containing 10 µl of carboxyfluorescein
(1.6 mg/ml; Molecular Probes) and incubated for 30 min at 25°C on a rocking platform.
Unbound dye was removed by centrifugation at 3,000 g for 2 min. After removing
unbound S.

gordonii from

the

plates

by

aspiration,

1 ml

of

labeled P.

gingivalis suspension (O.D.600 nm of 0.4) was added to each well and incubated for 24 hr
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on a rotary shaker under anaerobic conditions. To determine the functional activity of the
truncated Mfa1 polypeptides, S. gordonii cells were incubated with 1 uM of peptide (in
PBS) at 25°C for 30 min prior to adding the labeled P. gingivalis.
To visualize P. gingivalis/S. gordonii adherence and biofilm formation, unbound P.
gingivalis cells were removed by aspiration and coverslips were washed once with PBS.
Biofilms were fixed by incubating the coverslips with 1 ml of 4% paraformaldehyde for
5 min followed by two washes with PBS. The coverslips were then removed, placed face
down on a glass microscope slide containing a drop of anti‐fade reagent (Life
Technology) and sealed with nail polish. Visualization of biofilms was carried out by
laser scanning confocal microscopy on a Leica SP8 confocal microscope (Leica
Microsystems Inc.) using a 488 nm laser to detect labeled P. gingivalis and a 552 nm
laser to detect S. gordonii. Z‐plane scans of 25 µm in depth were collected at three
randomly chosen frames on each coverslip using a z‐step thickness of 0.7 µm.
Background noise was minimized using software provided with the Leica SP8 and three‐
dimensional constructions of the Z‐plane scans and quantification of total green and red
fluorescence was conducted using Volocity 6.3 Image analysis software (Perkin Elmer,
Akron, Ohio). Data were expressed as the ratio of total green (P. gingivalis) to red (S.
gordonii) fluorescence. Each experiment was carried out in triplicate and three
independent experiments were conducted for each peptide. A pairwise, nonparametric
analysis of variance was used to determine the statistical difference of

P.

gingivalis association with S. gordonii between the experimental and control samples.
A p value of <.05 was considered significant.
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2.5. SiteMap prediction of a putative binding cleft in Mfa1.
The Mfa1 protein structure (Protein Data Bank entry 5NF3) [100] was examined using
SiteMap v4.5.011 (Schrodinger Release 2017‐4). Standard parameters were used with a
maximum of 10 binding sites reported. The top six sites with a sitescore greater than 0.8
were examined further. Residues within 5 angstroms of the potential sites were identified
and the highest scoring site (sitescore 1.04) was used for validation by mutagenesis. The
five peptidomimetic compounds (pcp‐iii‐201, pcp‐iii‐206, pcp‐iii‐212, pcp‐iii‐293 and
pcp‐iv‐20) [141] were built and minimized using Macromodel (Schrodinger Release
2017‐4) and docked using Glide (Schrodinger Release 2017‐4) in SP mode centered on
the highest scoring site from SiteMap.
2.6. Site‐directed mutagenesis.
Site‐specific mutation reactions were carried out using the Quick‐change II XL Site‐
Directed Mutagenesis Kit (Agilent Tech) according to the manufacturer's protocol.
Mutagenic primers were designed such that the desired mutation was flanked by 10–
15 bp of mfa1 sequence and are listed in Table2.3. The reaction mixture contained 5 µl of
reaction buffer, 10 ng of plasmid pTCOW‐Mfa1 template DNA [94] (125 ng of each
primer, 1 µl dNTP mix, 1 µl of Pfu Ultra HF DNA polymerase (2.5 U/µl) and water to a
final volume of 50 µl. Cycling parameters were as follows: initial denaturation was
carried out at 95°C for 30 s, followed by 16 cycles of denaturation at 95°C for 30 s,
annealing at 55°C for 1 min and extension at 68°C for 14 min. After amplification,
products were immediately transferred to ice. A reaction containing pWhitescript 4.5‐kb
and primers supplied by the manufacturer was carried out simultaneously and served as
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positive reaction control. To eliminate parental plasmid following amplification, PCR
products were digested with DpnI for 1 hr at 37°C. Subsequently 1 µl of the digested
product was transformed into chemically competent E. coli XL10 blue cells (Agilent
Tech) by heat shock at 42°C for 45 s. The transformation reaction was transferred into
500 ul of pre‐warmed SOC medium (2% tryptone, 0.5% yeast extract, 10 mM NaCl,
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 mM glucose) and incubated at 37°C
for 1 hr with shaking at 225 rpm. Positive transformation was selected by plating on LB
agar plates supplemented with 100 µg/ml of ampicillin. Five positive colonies were
picked for plasmid extraction and successful mutation was confirmed by DNA
sequencing.

2.7. Random mutation.
Random mutagenesis was performed using GeneMorph II Random Mutagenesis kit
(Agilent Tech.) to generate additional mutations V238A, I252F and ΔK253. Briefly,
reactions contained 2 µg of plasmid pG‐N279, 5 µl of 10X Mutazyme II reaction buffer,
1 µl of 10 nM dNTP, 0.5 µl of primer mix (250 ng each), 1 µl Mutazyme II DNA
Polymerase (2.5 U/µl) and 41.5 µl of deionized water. The PCR profile was as follows:
denaturation at 95°C for 2 min, 20 cycles comprised of denaturation at 95°C for 30 s,
annealing at 60°C for 30 s and extension at 72°C for 1.5 min with final extension at 72°C
for 10 min. Following the amplification, PCR products were excised from an agarose gel
after electrophoresis, cloned into pGEX6p1 and transformed into chemically
competent E. coli BL21. Colonies were randomly chosen and plasmids were purified.
Successful mutation was confirmed by DNA sequencing.
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2.8. Complementation of P. gingivalis SMF1 with mutated Mfa.
Complementation of the Mfa1‐deficient P. gingivalis strain SMF1 was carried out using a
modification of the protocol previously described [94]. P. gingivalis SMF1 was grown on
a blood agar plate under anaerobic conditions for 2–3 days and donor E. coli S17‐1 was
grown aerobically on a LB agar plate. pTCOW‐mfa1 containing the desired mutation was
electroporated

into E.

coli strain

S17‐1

and

subsequently

conjugated

with P.

gingivalis SMF1 using the agar plate method. Briefly, cells from both donor and recipient
were scraped from the agar plates and spread on a 4 cm2 area on a blood agar plate
containing no antibiotics. After incubation for 24 hr, mixed cells from blood agar plates
were collected and incubated in TSBY supplemented with hemin (1 µl/ml) and
menadione (5 µl/ml) for 1 hr at 37°C under anaerobic conditions. Subsequently, 0.1 ml of
the cell suspension was plated on blood agar containing 20 µg of erythromycin per ml
and 200 µg of gentamicin per ml and was incubated anaerobically at 37°C for 10 days.
Transconjugants were subsequently grown in the presence of antibiotics and the purified
plasmid was confirmed to possess the desired mutation by DNA sequencing.

2.9. Cell surface expression of mutated Mfa1 polypeptides.
Cell surface expression of Mfa1 by the transconjugants was determined using an enzyme‐
linked immunosorbent assay (ELISA) after adsorption of P. gingivalis strains onto
Maxisorp plates (Nunc). Briefly, P. gingivalis cells were centrifuged at 3,000 g for 5 min
and cell pellets were washed there times with PBS. Subsequently, 107 cells were
incubated in each well for 2 hr at 4°C followed by washing with PBS to remove unbound
bacteria. Bound cells were incubated with rabbit rMfa monoclonal antibodies (1:5,000
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dilution) (Covance, Denver, PA) for 1 hr at 37°C. After washing with PBS, wells were
reacted with horseradish peroxidase‐conjugated goat anti‐rabbit antibody (1:3,000
[ImmuneReagents Inc.]) for 1 hr at 25°C. Antigen–antibody binding was determined by
adding 200 µl of 1× TMB ELISA substrate solution [3, 3′, 5, 5′‐tetramethylbenzidine]
(Invitrogen) and the reaction was incubated for 15 min at 25°C. Reactions were stopped
using 50 µl of stop solution (0.16 M H2SO4) and the endpoint was measured at 450 nm in
a Victor Multilabel counter (Perkin Elmer).

2.10. Mfa1 polymerization.
Whole cell lysates were prepared using a modification of the procedure previously
described by Hasegawa et al. [145]. Briefly, P. gingivalis strains were grown until early
stationary phase in TSBY media supplemented with hemin (5 µg/ml) and menadione
(1 µg/ml). Following centrifugation at 6,000 g for 5 min, cell pellets were collected and
suspended in 1× NuPAGE LDS sample buffer (Thermo Fisher) at the final OD of 2. The
cell suspensions were then denatured by incubation either at 60°C or 100°C for 10 min.
Following the heat treatment, the whole cell lysate was centrifuged at 20,000 g for
10 min to remove cellular debris, electrophoresed in 12% Bis‐Tris Plus gel (Thermo
Fisher) and Mfa1 was visualized by ELISA as described above.
2.11. Virtual screening of small molecule inhibitors. The structures of the NITVK and
VQDLL motifs of SspB were taken directly from the Streptococcus gordonii SspB Cterminal domain crystal structure (protein databank entry 2WZA) [146]. The structure
was processed using the Protein Preparation Wizard in Maestro (Schrödinger
Release 2018-1: Schrödinger, LLC, New York, NY, 2020). The similarity searches for
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the NITVK and VQDLL motifs were performed with Surflex-sim vers. 2.601 [147] using
two approaches. The first approach was to use all atoms of the peptide structures for the
NITVK and VQDLL motifs as the hypothetical ligand. The second approach was to use
the side chains of residues for the NITVK motif, and the side chains of residues VLL for
the VQDLL motif. The screened libraries were created from the ZINC [148] drug-like
library (ZINC 2014 version) containing 24,877,119 compounds and the ZINC 15 [149]
drug-like library (ZINC 2016 version) containing 17,244,856 compounds. The results
were ranked and the top 500 compounds of each screen were retained. Selection of
compounds was based on compound score, diversity, by eliminating compounds that
were structurally similar to a higher scoring compound, and finally compounds that were
commercially readily available for purchase.

Seventeen compounds and sixteen

compounds were purchased for the NITVK and VQDLL motifs, respectively.
2.12. Murine in vivo model of periodontitis. The protocol used in this study (protocol
16486) was approved by the Institutional Animal Care and Use Committee at the
University of Louisville under Federal guidelines for the use and care of laboratory
animals. Ten week old BALB/c/ByJ specific pathogen free mice were obtained from
Jackson Laboratory (Bar Harbor, ME) and housed in the University of Louisville
Research Resource Center animal facility. During the entire course of the study, mice
were fed with Lab Diet 5001 (Purina Mills, LLC, Gray Summit, MO).
Oral infection of the mice was carried out essentially as described by Deap et al. [135].
Prior to infection, mice were subjected to a combined antibiotic treatment for 10 days by
providing animals with water ad libitum containing 800 μg/ml sulfamethaxozole (MP
Biomedical, Solon, OH) and 400 μg/ml trimethoprim (Sigma, St. Louis, MO). Four days
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after conclusion of the antibiotic treatment, mice were infected by oral gavage with
109 cfu/ml of S. gordonii suspended in 2% carboxymethylcellulose (CMC; MP
Biomedical, Solon, OH) in sterile PBS using a 2.25 mm feeding needle (Popper and Son
Inc., New Hyde Park, NY). Infections were conducted every other day for a period of 10
days. Subsequently, mice were infected with 109 cfu/ml P. gingivalis suspended in 2%
CMC in PBS alone or in 2% CMC in PBS containing the small molecule inhibitors every
other day for 10 days. After the last infection with P. gingivalis, the mice were rested for
47 days and then euthanized by carbon dioxide asphyxiation.
To obtain the mouse skulls, the heads were removed and autoclaved for 15 min to remove
flesh and musculature.

The defleshed skulls were then immersed in 3% hydrogen

peroxide overnight at room temperature to remove any remaining flesh. The skulls were
submerged in deionized water to remove residual hydrogen peroxide, soaked in 1%
bleach solution for 30 sec, sonicated at 14 V for 1 min, and washed again with deionized
water. Samples were brushed using toothpaste, sonicated again in 1% bleach for an
additional 30 sec at 14 V and washed with water. The cleaned skulls were stained by
immersion in 1% methylene blue for 15 sec followed by washing with water until the
excess dye was removed.
To measure alveolar bone loss, a dissecting microscope fitted with a video imaging
marker measurement system (model VIA-170K; Fryer) was used.

Bone loss was

determined by measuring the distance between the alveolar bone crest (ABC) and
cemento-enamel junction (CEJ) at eight sites on the buccal sides of both left and right
maxillary molars. Bone loss was measured in mm for each group of mice and bone loss
data was normalized by subtracting the average bone loss that was observed in sham
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infected mice. Data was analyzed using one way ANOVA (Graph Pad Prism, La Jolla,
CA) and a pair wise parametric analysis of variance using a Bonferroni multiplecomparison post-test was used to determine the statistical difference among the
individual mouse groups. A p value of ≤0.05 was considered statistically significant.
2.13. Determination of IL-17 expression. To assess the level of IL-17 expression,
gingival tissue from the maxillary molar region was dissected from each mouse and fixed
in 4% paraformaldehyde overnight. Tissue samples were dehydrated by passing through a
series of ascending concentrations of ethanol and then cleared in xylene followed by
paraffin embedding. Tissue sections (5 – 6 μm in thickness) were prepared and mounted
on glass slides. Sections were deparaffinized by immersing in xylol twice for 15 min
each, and rehydrated by passing through absolute, 95% and 70% ethanol. Samples were
washed with distilled water to remove excess ethanol and epitope antigenicity was
recovered by microwave heating in water for 15 min. To prevent non-specific binding,
tissues were treated with 5% bovine serum albumin for 1 hr followed by reaction with IL17A monoclonal antibody conjugated with AlexaFluor 488 (eBioscience, San Diego, CA)
at 4oC for 24 hr. Binding of IL-17 monoclonal antibodies was observed using confocal
microscopy.

Three images were taken from each tissue section and IL-17

immunofluorescence quantification was performed using Volocity software.
2.14. Tissue culture. Human telomerase immortalized gingival keratinocytes (TIGKs)
[150] were cultured at 37°C in basal medium Dermalife K complete kit with Supplements
(LifeLine, Frederick, MD) and incubated for 5 days in an atmosphere of 5% CO 2 to
attained >95% confluence. The mouse macrophage cell line J774A.1 was grown in
Dulbecco modified Eagle medium (DMEM) (Thermo Fisher Scientific, Waltham, MA)
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supplemented with 4.5 g/ml glucose, 10% fetal bovine serum (FBS), and 100 U/ml
penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO). HL60 (ATCC® CCL240™)
cells were obtained from the American Type Culture Collection and cultured in
Iscove's Modified Dulbecco's Medium (Sigma-Aldrich, St. Louis, MO) supplemented
with 20% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO). Both J774A.1 and
HL60 cells were incubated at 37°C in an atmosphere of 5% CO2 for 4 days to reach
>95% confluence.
2.15. Determination of lactate dehydrogenase activity. CytoTox 96 nonradioactive
cytotoxicity assay (Promega Inc. Madison, WI) was used to determine extracellular
lactate dehydrogenase activity (LDH) in TIGK, J774A.1 and HL60 cell cultures treated
with the test compounds. Briefly, cells were inoculated in a 96 well microtiter plate at an
initial density of 4000 cells per well and grown at 37°C in an atmosphere of 5% CO2 for
24 hr. The spent medium was removed and replaced with fresh medium containing the
desired concentration of the compound. After 18 hr incubation, the cell supernatant was
collected by centrifugation at 250 × g for 4 min and 50 µl of cell free supernatant was
transferred into wells of a fresh 96 well microtiter plate. Subsequently, 50 µl of LDH
substrate was added in each well and incubated at room temperature for 30 min.
Reactions were stopped by adding 50 µl of stop solution according to the manufacturer’s
protocol and the end point was measured by determining optical density at 490 nm. Cells
treated with culture medium containing 0.1% DMSO or with medium alone served as
negative controls and cells incubated with 15 µl lysis buffer (supplied by manufacturer)
for 1 hr served as a positive control for lysis. All samples were tested in triplicate.
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2.16. Measurement of total cellular ATP. To determine the metabolic activity of cells,
the total cellular ATP level was measured in cell culture samples using CellTiterGlo
reagent (Promega Inc. Madison, WI). Cells were grown as described above in the
presence of the desired concentration of compounds. The spent medium was decanted
and cells were washed three times with PBS and subsequently incubated with 100 μl of
CellTiterGlo substrate.

To facilitate the reaction, plates were incubated at room

temperature for 2 min with shaking and for an additional 10 min without shaking. Total
light production was measured using a Victor 3 multilabel plate reader (PerkinElmer).
2.17. Determination of apoptotic activity. The apoptotic activity of the compounds was
determined using the phycoerythrin (PE) annexin V/dead cell apoptosis kit with SYTOX
green for flow cytometry (Invitrogen, Carlsbad, CA). Cells were grown in 12 well flat
bottom microtiter plates at an initial density 2 × 105 cells in 1.5 ml medium per well for
24 hr. Following the incubation period, spent medium was replaced with fresh medium
containing the desired concentration of the test compound and incubated for another 18
hr. After trypsinization, cells were harvested by centrifuging at 250 × g for 4 min and the
cell pellet was suspended in 100 μl of binding buffer supplemented with 1 μl Sytox and 5
μl annexin V followed by incubation at 37°C for 15 min. Samples were then diluted by
adding 400 µl binding buffer and flow cytometry was performed using a FACScalibur
flow cytometer (Becton Dickinson, Franklin Lakes, NJ), measuring the fluorescence
emissions at 530 nm and 575 nm. Cells treated with medium alone or with medium
containing 0.1% DMSO served as negative controls, while cells treated with 2 mM
hydrogen peroxide at 37°C for 4 hr served as a positive control for apoptosis.
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2.18. Measurement of hemolytic activity. The hemolytic activity of compounds was
determined using both sheep and human red blood cells. Briefly, 100 μl of 1% sheep or
human erythrocytes (BioreclamationIVT, MD) was suspended in 1 ml of sterile PBS
containing 5% FBS and the appropriate concentration of compound was added. The cell
suspension was incubated at 37°C for 3 hr, centrifuged at 3,500 × g for 5 min, and a 200
μl aliquot of the cell free supernatant was transferred into each well of a 96-well
microtiter plate. Hemolytic activity was measured by quantifying hemoglobin release in
the supernatant using a Victor 3 multilabel plate reader (PerkinElmer, Waltham, MA) at a
wavelength of 538 nm. All samples were analyzed in triplicate. Erythrocytes suspended
in PBS with 5% FBS served as a negative control, and erythrocytes that were lysed by
suspension in distilled water (dH2O) served as a positive control.
2.19. Statistical analysis: For each of the cytotoxicity assays described above, data was
analyzed using a pair wise non parametric t test using GraphPad Prism version 8.0. A p
value<0.05 is considered as statistically significant.
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CHAPTER THREE: IDENTIFICATION AND CHARACTERIZATION OF
FUNCTIONAL MOTIFS OF MFA1
3.1. Introduction: Periodontal disease is the sixth most prevalent disease in the world
and approximately 50% of adults in the USA suffer from some form of periodontitis [6,
9].

The human oral cavity is home to ~700 species of bacteria and maintaining

host/microbe homeostasis is key to maintaining periodontal health.

Porphyromonas

gingivalis is strongly associated with chronic adult periodontitis and is an important
pathogen that is capable of modulating the host immune response and disrupting normal
host/microbe homeostasis [151, 152]. This can lead to the development of a dysbiotic
microbial community which can induce uncontrolled inflammation leading to the
destruction of tooth supporting tissues, and ultimately tooth loss [41-43]. Periodontitis is
also associated with increased risk of other systemic diseases such as rheumatoid
arthritis, cardiovascular disease, some cancers, and chronic respiratory disease [27, 153,
154].
The primary niche for P. gingivalis is the subgingival pocket but the organism also
adheres efficiently to supragingival bacteria such as various commensal streptococci
[70, 87, 127]. Indeed, adherence to streptococci can modulate the pathogenic potential of
P. gingivalis [51, 135, 155] and may also be important for the initial colonization of the
oral cavity by the organism. Thus, adherence of P. gingivalis to streptococci represents a
viable target for therapeutic intervention.
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P. gingivalis adherence to streptococci is

driven by a protein-protein interaction between the minor fimbrial antigen, Mfa1, and the
streptococcal antigen I/II protein [71, 87, 94, 156].

Deap et al. identified several

discrete structural motifs in SspB that are essential for adherence and suggested that this
functional region resembles the eukaryotic nuclear receptor (NR) box protein-protein
interaction domain [136]. In addition, a synthetic peptide (BAR) that encompasses this
region potently inhibited P. gingivalis/streptococcal adherence in vitro and significantly
reduces P. gingivalis virulence in vivo

[135]. Subsequently, Patil et al. designed and

synthesized small molecule BAR peptidomimetics that potently inhibit P. gingivalis
adherence [141, 157].

Thus, the binding region in antigen I/II has been well

characterized but little is known about the binding domains or motifs of Mfa1 that
contribute to this protein-protein interaction.
In this chapter, N‐ and C‐terminal truncated Mfa1 polypeptides were shown to inhibit P.
gingivalis/streptococcal adherence and suggested that Mfa1 functional motifs are present
between residues 225–400 of the protein. Using the three‐dimensional structure of Mfa1
[100], a putative binding cleft was identified using the prediction tool SiteMap. Site‐
specific mutation of amino acids in the predicted cleft, for example, R240A, W275A,
D321A and A357P inhibited the interaction of Mfa1 with streptococci. Finally,
complementation of an Mfa1‐deficient P. gingivalis strain with wild‐type mfa1 restored
adherence to streptococci, whereas complementation with the site‐specific mfa1 mutants
resulted in significantly reduced levels of adherence. Together, these results identify
specific residues and motifs that are important for the Mfa1/SspB protein–protein
interaction.
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3.2. Results.
3.2.1 Localization of Mfa1 functional domains
To identify regions of Mfa1 that contribute to the interaction with antigen I/II, a series of
N‐ and C‐terminal truncated Mfa1/GST fusion proteins were constructed and expressed.
The truncated Mfa1 polypeptides were purified by affinity purification and the GST tag
removed by in column cleavage and were designated as N194, N225, N279, N400 and
C280 as shown in Figure 3.1. The functional activity of these peptides was determined by
assessing their ability to inhibit P. gingivalis/S. gordonii adherence and biofilm formation
using the dual species biofilm model described previously by Patil et al.[141].
Representative images of biofilms formed in the presence of each peptide are shown in
Figure 3.2a and inhibition results are summarized in Figure 3.2b. Peptides N194 and
N225 were relatively poor inhibitors of P. gingivalis adherence (~20% inhibition)
compared to the full‐length Mfa1 protein (80% inhibition). In contrast, peptide N279
exhibited 70% inhibition and adherence inhibition by peptide N400 was similar to that of
the full‐length Mfa1 protein. Peptide C280 exhibited reduced activity (~40% inhibition)
compared to peptides N279 and N400 but was significantly more active than peptides
N194 and N225. Together, these results suggest that essential functional residues that
contribute to P. gingivalis adherence to streptococci reside in the region of Mfa1
comprising amino acids 225–400.
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Figure 3.1. Schematic representation of the series of Mfa1 peptide fragments: The
full‐length Mfa1 lacking the signal peptide (21–563aa residues), and N‐terminal peptide
fragments N194, N225, N279 and N400 encoding residues 21–194, 21–225, 21–279 and
21–400, respectively, are shown. The C‐terminal peptide fragment, C280, is comprised of
Mfa1 residues 280–563.
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Figure 3.2. Determination of the inhibitory activity of the peptides: A) Peptide
mediated inhibition of P. gingivalis adherence in a dual species biofilm model
comprising S. gordonii (red) and P. gingivalis (green). Panels (a) PBS treated, (b), (c),
(d), (e), (f) and (g) were treated with peptides N194, N225, N279, N400, full‐length Mfa1
and C280, respectively. (B) Quantification of relative adherence of P. gingivalis and S.
gordonii was determined by VOLOCITY software. Each experiment was carried out in
triplicate and three independent experiments were conducted for each peptide.
Comparisons of biofilms formed in PBS (control) with peptide‐treated biofilms were
carried out using one way ANOVA followed by Dunnett’s multiple comparison test.
*p < .05.

44

3.2.2. In silico prediction of a putative Ag I/II binding cleft in Mfa1
To further highlight the functional region(s) of Mfa1, we took advantage of the recently
published three‐dimensional structure of Mfa1 [100] to predict putative binding clefts
using SiteMap. In addition, a series of in silico docking experiments were conducted
using five peptidomimetic compounds that mimic the BAR peptide and were previously
shown by Patil et al. [141, 157] to be potent competitive inhibitors of P. gingivalis/S.
gordonii adherence. As shown in Figure 3.3a, all five of the mimetic compounds could be
docked in the putative binding cleft that exhibited the highest sitescore by SiteMap.
Amino acids of the Mfa1 protein that comprise the putative binding cleft are highlighted
in red and underlined in Figure 3.3b.
To validate the predicted binding cleft, a series of Mfa1 site‐specific mutant peptides that
targeted residues and putative motifs predicted in Figure 3.3b to comprise the binding
cleft were constructed and expressed. Since the results of the truncated Mfa1 peptides in
Figure 3.2.b indicated that the region comprising residues 226–279 was important for P.
gingivalis adherence, site‐specific mutations R240A and W275A were introduced into
peptide N279 since both of these residues are predicted by SiteMap to be part of the
binding cleft. Additional mutations, D321A and A357P, were also constructed in peptide
N400 to disrupt two predicted amphipathic helices in the putative binding cleft (residues
321–329 and 351–364). Finally, several additional residues in peptide N279 that were not
predicted to comprise the binding cleft were tested (e.g., V238A, I252F and ΔK253). As
shown in Figure 3.4., peptides N279 and N400 inhibited P. gingivalis adherence to
streptococci by 66% and 79%, respectively, consistent with the results shown in Figure
3.2b. Polypeptide N279 containing the R240A or N275A mutations were significantly
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less potent inhibitors relative to the parent N279 peptide, exhibiting only 32% and 38%
inhibition of P. gingivalis adherence, respectively.

Figure 3.3.(a) Three‐dimensional
structure of the Mfa1 with a
composite of five peptidomimetic
adherence inhibitory compounds
docked in a putative binding cleft.
The residues that comprise the
predicted binding cleft shown in “a”
are shown in red underlined text in
the Mfa1 sequence (b) or highlighted
in red in the Mfa1 structure (c). The
positions of residues R240 and W275
(see text) are shown in green and
cyan, respectively.
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In addition, peptide N279 containing both mutations, R240A and W275A exhibited
significantly lower inhibitory activity than either of the peptide fragments containing a
single mutation. In contrast, peptide N279 containing the mutations V238A, I252F or
ΔK253 showed no significant reductions in inhibitory activity. Furthermore, mutations
D321A and A357P, intended to disrupt the two putative helices, also reduced inhibitory
activity relative to the parent N400 peptide (79% to 59% and 79% to 38%, respectively).
Together, these results provide preliminary validation of the binding cleft predicted by
SiteMap and identify specific Mfa1 residues that contribute to adherence of P.
gingivalis to streptococci.
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Figure 3.4. Inhibition of P. gingivalis adherence to S. gordonii by mutated Mfa1
peptides. Each experiment was carried out in triplicate and three independent
experiments were conducted for each peptide. Biofilms treated with parent and mutated
peptides were compared and analyzed using an unpaired T test. ***p < .05, ns, not
statistically significant.
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3.2.3. Complementation of Mfa1‐deficient P. gingivalis with site‐specific Mfa1
mutants
To further confirm the functional roles for R240 and A357, full‐length Mfa1 polypeptides
containing the R240A and A357P mutations were constructed and introduced into the
Mfa1‐deficient strain P. gingivalis SMF1. As shown in Figure 3.5a, cell surface
expression of Mfa1 was significantly reduced in P. gingivalis SMF1 compared to the
wild‐type strain, P. gingivalis 33277. Complementation of P. gingivalis SMF1 with wild‐
type mfa1 or with the site‐specific mutants restored cell surface expression of Mfa1 to
wild‐type levels (Figure 3.5a). Consistent with its level of cell surface expression,
adherence of P. gingivalis SMF1 to streptococci was significantly reduced relative to the
parent strain 33277 but was restored to wild‐type levels by complementation with full‐
length mfa1, as shown in Figure 3.5b. In contrast, although complementation with Mfa1
containing either the R240A or A357P mutations restored cell surface expression, both of
these complemented strains showed significantly reduced levels of adherence to
streptococci. Indeed, adherence by the complemented strain expressing Mfa1‐A357P was
indistinguishable from P. gingivalis SMF1 (Figure 3.5b).
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Figure 3.5. Complementation of P. gingivalis SMF1 with wild‐type and site‐specific
mutants of Mfa1. (a) Cell surface expression of Mfa1 was determined by ELISA using
polyclonal anti‐Mfa1 antibodies. Cell surface expression was normalized to the level of
Mfa1 expression in wild‐type P. gingivalis 33277. (b) Adherence of P. gingivalis to
streptococci was determined using a two species biofilm model as described in Materials
and Methods. Each experiment was carried out in triplicate for each group. Adherence
data were normalized to the level of adherence of the wild‐type P. gingivalis 33277 and
data were analyzed using an unpaired T test. ***p < .001, **p < .01, ns, not statistically
significant.
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3.2.4. Polymerization of wild‐type and mutant Mfa1 proteins
In vivo, P. gingivalis Mfa1 is post‐translationally modified by glycosylation [92] and
likely polymerizes to form the intact minor fimbrial structure by a donor strand based
assembly mechanism involving both N‐ and C‐terminal domains in Mfa1 [100, 101]. In
addition, intact minor fimbriae resist complete denaturation by SDS unless samples are
incubated at 100°C [94, 158]. To determine whether the mutations described above affect
Mfa1 polymerization, P. gingivalis cells were suspended in 1x LDS buffer and incubated
at either 100°C or 60°C. As shown in Figure 3.6a, incubation at 100°C resulted in a
single protein band of 67 kDa in all samples except the Mfa1‐deficient SMF1 strain,
consistent with the completely denatured Mfa1 polypeptide. In contrast, incubation at
60°C produced a high molecular weight smear in all samples except strain SMF1
(Figure 3.6b), indicating that incomplete denaturation of the minor fimbriae had occurred.
Mfa1 proteins containing either R240A or A357P mutations behaved similarly to the
wild‐type protein in the 33277 and complemented cSMF1 strains, suggesting that these
mutations do not affect Mfa1 processing or polymerization and that the strains expressing
the mutated Mfa1 polypeptides are still capable of producing intact minor fimbriae.
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Figure 3.6. Denaturation of P. gingivalis minor fimbriae. P. gingivalis cells were
suspended in 1× LDS buffer and incubated either at (a) 100°C or (b) 60°C for 10 min.
Extracts were electrophoresed in a 12% Bis‐Tris gel and after transfer, Mfa1 was
visualized using polyclonal anti‐Mfa1 antibodies. Lanes 1, P. gingivalis ATCC 33277;
2, P. gingivalis SMF1; 3, P. gingivalis cSMF1; 4, P. gingivalis cMF1‐R240A; and 5, P.
gingivalis cSMF1‐A357P; M, size markers.
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3.3. Discussion: Heterotypic community formation of P. gingivalis with oral streptococci
is driven by a protein–protein interaction between the minor fimbrial antigen (Mfa1) of P.
gingivalis and streptococcal surface antigen I/II, for example, SspB of S. gordonii [71,
87, 94]. This interaction has been shown to modulate the virulence potential of P.
gingivalis [43, 51] and may also be important for initial colonization of the oral cavity
by P. gingivalis. Therefore, disruption of heterotypic community formation by targeting
the Mfa1/antigen I/II interaction may represent a potential therapeutic approach to
control P. gingivalis colonization and virulence [135, 142, 159] [135, 142, 159]. The
region of antigen I/II involved in the interaction with Mfa1 has been extensively
characterized [134, 135, 160] and these studies led to the development of both peptide
and small molecule peptidomimetics that potently inhibit P. gingivalis/streptococcal
adherence in vitro and significantly reduced P. gingivalis virulence in vivo [135, 141,
142, 161]. However, the interacting interface of Mfa1 that drives this protein–protein
interaction has not been well characterized.
Based on peptide mapping, our results indicate that important functional residues and/or
motifs of Mfa1 reside between residues 225 and 400 of the protein and truncated peptides
comprising this region inhibited P. gingivalis adherence to streptococci as effectively as
the full‐length Mfa1 protein. In addition, analysis of the three‐dimensional structure of
Mfa1 using SiteMap identified a putative ligand binding cleft in which five small
molecule mimetics of the BAR peptide could be readily docked. Interestingly, many of
the residues within five angstroms of the peptidomimetic ligands are present in the 225–
400 residue region of Mfa1. BAR peptide can also associate with this site but docking
studies using the more structurally complex peptide will require further refinement. The
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functional properties of several of these residues were confirmed by site‐specific
mutagenesis and peptides containing the R240A, W275A or A357P mutations were
significantly less effective inhibitors of P. gingivalis adherence that the parent peptide or
full‐length Mfa1. Amino acids R240 and W275 form hydrogen bonds with residues that
stabilize the binding cleft and those residues are directly accessible in the binding site
pocket. The A357P mutation likely disrupts a short amphipathic α‐helix in the binding
site pocket and we can speculate that this region may interact with the amphipathic
VQDLL motif of BAR peptide which is essential for its interaction with Mfa1.
Consistent with this, complementation of an Mfa1‐deficient strain of P. gingivalis with
full‐length copies of Mfa1 containing the R240A, W275A or A357P mutations did not
restore P. gingivalis adherence whereas complementation with native Mfa1 restored the
wild‐type phenotype. Even though the Mfa1/Ag I/II interaction is essential for P.
gingivalis adherence and stable biofilm formation, it should be noted that inactivation
of mfa1 did not completely eliminate adherence to streptococci in vitro. One explanation
for this is that the major fimbrial subunit protein, P. gingivalis FimA, can also interact
with streptococcal cell surface GAPDH [88] ; however, this interaction by itself is
insufficient to promote stable P. gingivalis‐streptococcal biofilms

[127]. Together,

these results validated the ligand binding cleft identified by SiteMap, identified specific
amino acids that contribute to P. gingivalis adherence and suggest that the central region
of Mfa1 is essential for the interaction of the minor fimbriae with the BAR motif of
streptococcal antigen I/II.
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Biogenesis of the minor fimbriae in P. gingivalis requires proteolytic and post‐
translational processing of Mfa1 and subsequent polymerization to form the fimbrial
structure, most likely via a donor strand based exchange mechanism. Polymerization of
Mfa1 may involve β‐strands at both the N‐ and C‐terminal regions of Mfa1 [100, 101].
In contrast, our results indicate that the central region of Mfa1, between residues 225 and
400, is required for P. gingivalis adherence to streptococci and consistent with this, the
highest scoring ligand binding cleft identified by SiteMap is mostly comprised of
residues in this central domain. Furthermore, the polymerization of mutated Mfa1
peptides that are defective in streptococcal adherence was similar to the wild‐type Mfa1
protein, suggesting that independent domains of Mfa1 are required for fimbrial
biogenesis and P. gingivalis‐streptococcal adherence. Consistent with this, it was recently
shown that peptides CT1 and CT2 which are both derived from the C‐terminal region of
Mfa1 encompassing residues 546–563 inhibit Mfa1 polymerization [162]. Peptide CT2
also inhibited P. gingivalis‐streptococcal biofilm formation and functioned by interfering
with minor fimbrial biogenesis. In contrast, the BAR peptide and the BAR
peptidomimetics function as competitive inhibitors of streptococcal adherence and have
no effect on minor fimbrial biogenesis. The mature minor fimbriae of P. gingivalis also
contain three additional tip proteins, Mfa3, Mfa4 and Mfa5. These proteins appear to play
a role in the assembly of the tip complex itself and its incorporation into the fimbrial shaft
and are required for optimal surface expression of the minor fimbriae [106, 107, 145].
While Mfa1 has been shown to interact with Mfa3 [101], there is little information to
suggest that the tip proteins contribute directly to P. gingivalis adherence to streptococci.
Indeed, purified recombinant Mfa1 in the absence of the tip proteins potently inhibits P.
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gingivalis adherence, suggesting that Mfa3, Mfa4 and Mfa5 do not play a major role in
the interaction with streptococcal antigen I/II.
Although several specific amino acids and/or structural motifs of Mfa1 were shown to be
important for its interaction with Ag I/II, the functional properties of other residues
predicted to comprise the ligand binding cleft have yet to be determined. For example,
K70 and Mfa1 amino acids 180–194 were identified as putative cleft residues; however,
the truncated peptide N225 was only a poor inhibitor of P. gingivalis adherence. This
suggests that these residues may not interact directly with Ag I/II (or the BAR peptide),
or alternatively, that they may also require the contribution of downstream residues.
Since Mfa1 has been recently crystallized [100], it may be possible to co‐crystallize the
protein with the BAR peptide or with recently developed peptidomimetics of BAR [161]
to generate a more complete picture of the Mfa1‐Ag I/II interacting interface. Ultimately,
a thorough understanding of the mechanism of the Mfa1/Ag I/II interaction will facilitate
structure‐based drug design and the development of potential therapeutics that may
limit P. gingivalis colonization of the oral cavity.
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CHAPTER FOUR: SMALL MOLECULE DRUG DISCOVERY
4.1. Introduction : Treatment of periodontal disease typically involves the mechanical
removal of dental plaque by scaling and root planning, antibiotic therapy, and if
necessary, gingival surgery to reduce the depth of the subgingival pocket [163].
Although periodontal disease is considered to be a polymicrobial infection,
Porphyromonas gingivalis has been suggested to function as a keystone pathogen that
can alter host innate immune functions leading to dysbiosis and chronic inflammation
[41, 52, 152]. The primary niche of P. gingivalis is the subgingival pocket [54, 164] but
initial colonization of the oral cavity by P. gingivalis occurs in the supragingival biofilm
where the organism can adhere to primary colonizing organisms such as oral streptococci
[59] [72]. Adhesion of P. gingivalis to streptococci is primarily driven by a proteinprotein interaction between the minor fimbrial antigen of P. gingivalis (Mfa1) and
specific members of the streptococcal surface antigen I/II family of proteins (e.g., SspB
of S. gordonii) [94, 127, 135]. As one of the initial interactions contributing to P.
gingivalis colonization, this protein-protein interaction represents an ideal candidate for
therapeutic intervention.
The interaction of Mfa1 with SspB has been well characterized. Deap et al. identified
two discrete motifs of SspB comprised of the amino acids NITVK and VQDLL and
showed that these motifs are essential for the interaction with Mfa1 [134]. Daep et al.
also showed that these motifs in SspB closely resembled the functional motifs of the
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eukaryotic nuclear receptor (NR) box protein-protein interaction domain [134, 136].
Furthermore, a synthetic peptide containing both NITVK and VQDLL (designated BAR)
potently inhibited P. gingivalis adhesion to S. gordonii and significantly reduced P.
gingivalis virulence in a murine model of periodontitis [135, 136]. Subsequently, Patil et
al. synthesized a series of highly active small molecule peptidomimetics of BAR using a
click chemistry approach and demonstrated that these compounds exhibited no toxicity
towards a variety of human cells and cell lines [141, 142].
The advent of computer assisted molecular modeling technologies and structure-based
virtual screening methods provides an additional platform for rational drug design to
identify targeted small molecule inhibitors of biologic interactions. For example, Stone
et al. utilized a high throughput virtual screening approach of the ZINC database of
commercially available chemical compounds to identify small molecule inhibitors of P.
gingivalis m-diaminopimelate dehydrogenase, an essential enzyme involved in protein
and cell wall synthesis [165]. In this chapter, I performed virtual screening of the ZINC
drug-like chemical libraries to identify small molecule homologs similar to the NITVK
and VQDLL motifs of SspB. The three most potent compounds that were identified
inhibited P. gingivalis adherence to streptococci and reduced P. gingivalis virulence in
vivo. Two of these active compounds showed no cytotoxic activity towards a variety of
human and murine cell lines and represent potential lead compounds for the development
of novel therapies to limit P. gingivalis colonization of the oral cavity.
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4.2. Results:
4.2.1. In vitro functional assessment of the identified ZINC library candidates. After
virtual screening, a total of 33 commercially available molecules with structural
similarity to either the NITVK or VQDLL motifs were identified and obtained for
functional testing. Using the two species biofilm model described by Patil et. al. [141],
the in vitro effectiveness of the compounds was determined by their ability to inhibit P.
gingivalis adherence to S. gordonii and subsequent biofilm formation at an initial
concentration of 40 µM. As shown in Figure 4.1A, of the 17 compounds selected based
on similarity with the NITVK motif, two inhibited adherence and biofilm formation at
≥40%, N7 (~40%) and N17 (~60%). In addition, of the 16 selected compounds based on
similarity with the VQDLL motif, only compound V8 inhibited biofilm formation by
≥40% (Figure 4.1B). Subsequently, dose dependent inhibition studies were carried out
for compounds N7, N17 and V8 using concentrations of 5, 10, 15, 25 and 40 µM. As
shown in Figure 4.2, each of these compounds inhibited P. gingivalis adherence and
biofilm formation in a dose dependent manner. The structure of the N7, N17 and V8
presented in Figure 4.3a, b and c respectively and Figure 4.3.d and 4.3.e indicate the
structural similarities between N17 and NIVTK, and V8 and VQDLL motifs. Thus,
compounds that are similar to both of the functional domains of the streptococcal SspB
protein inhibited P. gingivalis/S. gordonii adherence in vitro.
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Figure 4.1. In vitro screening of the small molecules. Compounds N1 – N17 (A) and
V1 – V16 (B) were screened for inhibition of P. gingivalis adherence to S. gordonii at a
concentration of 40 µM. Relative inhibition was normalized to the PBS control. Each
experiment was carried out in triplicate and three independent experiments were
conducted for each compounds. Data was analyzed by one way ANOVA followed by
Dunnett’s multiple comparison test using PBS as control. Significance was defined as
*p<0.05, **p<0.01, ***p<0.001.
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Figure 4.2. Dose dependent inhibition of P. gingivalis adherence. Compounds N7,
N17 and V8 were each tested at concentrations of 5, 10, 15, 25 and 40 µM and inhibition
was normalized to the PBS control.
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A.

C.

B.

N7:
ZINC000004797470

N17: ZINC03142014

C.

D.

Figure 4.3.

V8: ZINC84110921

Chemical structures of the lead compounds:

A) N7: 1-(4-

chlorophenoxy)-3-{2-imino-3-[2-(piperidin-1-yl)ethyl]-2,3-dihydro-1H-1,3-benzodiazol1-yl}propan-2-ol

hydrochloride,

B)

N17:

N-(2-hydroxyphenyl)-2-{3-[(2-

hydroxyphenyl)carbamoyl]phenyl}-1,3-dioxo-2,3-dihydro-1H-isoindole-5-carboxamide,
C)

V8:

N-(1-cyanocyclopentyl)-2-[3-(5-methyl-1H-pyrazol-3-yl)piperidin-1-yl]

acetamide, D) overlay of compound N17 on the NITVK motif, E) overlay of compound
V8 on the VXXLL motif. In the overlay images, compounds N17 and V8 are indicated
with the tan backbones and the AgI/II motifs are shown with the blue backbones.

62

4.2.2. Small molecule inhibition of P. gingivalis virulence.

In vivo activity of

compounds N7, N17 and V8 was determined using a murine model of periodontitis as
described by Deap et al. [135] (Figure 4.4). Briefly, Antibiotic pretreated mice were
challenged with 109 cfu/ml of S. gordonii suspends in 2% carboxyl methyl cellulose
(CMC) using feeding needle for 10 days in every other days. Then mice were infected
with P. gingivalis in same way of S. gordonii in presence or absence of the compounds at
concentration of 40µM. After 47 days of post infection, mice were euthanized and mice
maxillary was recovered. Since a hallmark of periodontal disease in humans is the
resorption of alveolar bone anchoring the teeth, P. gingivalis virulence was assessed by
alveolar bone loss, determined by measuring the distance from the alveolar bone crest
(ABC) to the cemento enamel junction (CEJ).

Figure 4.5A shows representative images

of the maxillary jaws of treated and untreated animals. Infected but untreated mice
exhibited an uneven ABC and more extensive exposure of tooth roots (arrows in Figure
4.5A) than control animals or mice treated with N1, N17 or V8. The quantification of
bone loss for each group of mice is shown in Figure 4.5B. Consistent with our previous
results [135], mice infected with both S. gordonii and P. gingivalis showed significantly
greater alveolar bone loss than sham-infected mice or animals infected with S. gordonii
or P. gingivalis alone. In contrast, infection of mice with S. gordonii and P. gingivalis in
the presence of N7, N17 or V8 resulted in a significant reduction in alveolar bone loss
(p<0.001).
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Figure 4.4: Schematic timeline of the mice model of periodontitis. Mice were treated
with sulfamethoxazole and trimethoprim in water for 10 days ad libitum. Antibiotic
pretreated mice were challenged with 109 cfu/ml of S. gordonii suspends in 2% carboxyl
methyl cellulose (CMC) using feeding needle for 10 days in every other days. Then mice
were infected with P. gingivalis in same way of S. gordonii in presence or absence of the
compounds. After 47 days of post infection, mice were euthanized and alveolar bone loss
was measured.

64

A.
P. g-S. g

P. g-S. g +N17

P. g-S. g+N7

P. g-S. g+V8

B.
***

*
0.05

*
ns

0.00

-0.05

65

V8

7
N

17
N

on
ii
in
gi
va
lis
P.
g+
S.
g

P.
g

or
d

Sh
a

m

-0.10

S.
g

Bone loss(mm)

ns

Figure 4.5. In vivo inhibition of P. gingivalis virulence. A) Representative images of
maxillary molars of mice infected with P. gingivalis and S. gordonii and treated with
compounds N7, N17 or V8 at a concentration of 40 µM. B) Quantification of alveolar
bone loss. Bone loss was determined by measuring the distance from the alveolar bone
crest to the cemento-enamel junction and values were normalized against sham infected
mice. Each group had eight mice. Statistically significant differences were determined
using one way ANOVA. *p<0.05; ***p< 0.001; ns, not significant.
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Furthermore, since IL-17-mediated recruitment of neutrophils is an important contributor
to the inflammatory process leading to alveolar bone resorption [166, 167], we also
determined whether treatment with N7, N17 or V8 influenced the level of IL-17
expression in gingival tissue relative to untreated animals. As shown in Figure 4.6, IL-17
expression was significantly increased in mice infected with both S. gordonii and P.
gingivalis relative to animals infected only with S. gordonii. Treatment of dual infected
mice with each of the compounds significantly reduced IL-17 expression in the maxillary
gingiva to levels similar to that in mice infected with S. gordonii alone. Together, these
data indicate that treatment with each of the three lead compounds resulted in reduced
gingival inflammation and reduced alveolar bone loss in mice infected with both S.
gordonii and P. gingivalis.
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Figure 4.6. IL-17 levels in gingival tissue. A) IL-17 expression was determined by
immunofluorescence staining of maxillary gingival tissue obtained from mice infected
with S. gordonii alone, S. gordonii and P. gingivalis or from dual infected animals treated
with compound N7, N17 or V8. B) Quantification of IL-17 expression in control and
treated mice. Experiment in each group carried out in triplicate. One way ANOVA was
performed to determine statistical significance. ***, p<0.05.
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4.2.3. Determination of cytotoxicity of the active compounds. To confirm that N7,
N17 and V8 function by inhibiting P. gingivalis adherence to S. gordonii rather than
acting as an antibiotic, microbicidal activity of the compounds was determined by
growing the organisms in medium containing 40 µM of each compound for 24 hr. As
shown in Figure 4.7, none of the compounds affected the growth of S. gordonii or P.
gingivalis either in early stage or late stage of growth.
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Figure 4.7. Bacteriocidal activity of the compounds. S. gordonii (A) and P. gingivalis
(B) were grown for 24 hr in medium containing 40 µM of each compound and growth
was quantified by measuring OD600nm for each culture. Each experiment carried out in
triplicate.
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Next, to assess compound cytotoxicity towards eukaryotic cells, a series of toxicity tests
were carried out using telomerase immortalized human gingival keratinocytes (TIGK)
and the murine J774.A1 and human HL-60 cell lines. These tests included measuring
lactate dehydrogenase (LDH) release and overall cell viability (cellular ATP levels) of
cells after treatment with each compound. In addition, the apoptotic and hemolytic
activity of each compound was determined. As shown in Figure 4.8, LDH release by
cells treated with compounds N17 and V8 did not significantly differ from the negative
controls for any of the cell lines. In contrast, exposure of cells to N7 resulted in a
significant increase in LDH release at the higher concentrations that were tested (20 – 40
µM) suggesting that this compound may disrupt the integrity of the cell membrane.
Compounds N17 and V8 also exhibited minimal effects on cell viability, measured by
total ATP levels, whereas N7 significantly reduced cellular ATP levels (Figure 4.9).
Consistent with the results above, N17 and V8 did not induce apoptosis over the control
reaction whereas treatment with compound N7 significantly reduced the live cell count
and increased the number of late apoptotic cells (Figure 4.10) and Table 4.1, 4.2 and 4.3.
Finally, as shown in Figure 4.11, none of the compounds exhibited hemolytic activity
towards either sheep or human red blood cells. Together, these data indicate that N17
and V8 exhibit little cytotoxic activity towards the eukaryotic cell lines tested.

In

contrast, compound N7 exhibited significant cytotoxicity and may not be biocompatible.
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Figure 4.8. LDH assay: Cytolytic activity of compounds N7, N17 and V8 against TIGK
(A), J774A.1 (B), and HL60 (C) cells. LDH activity in cell free medium supernatants
was determined after incubation of cells with the compounds for 18 hr at a concentration
5, 20 or 40 µM. *p<0.05, **p<0.01.
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Figure 4.9. ATP assay: Effect of compounds N7, N17 and V8 on TIGK (A), J774A.1
(B), and HL60 (C) cell viability. Cellular ATP levels were determined after treating cells
with the compounds for 18 hr at a concentration 5, 20, or 40 µM. Significant differences
were determined by comparing experimental samples to the medium only and
medium/DMSO controls. *p<0.05, ***p<0.001, ns – not significant.
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Figure 4.10. Cell death caused by the compounds.

Induction of apoptosis by

compounds N7, N17 and V8. HL60 cells were treated for 18 hr with each compound (5,
20 or 40 µM) and apoptosis was quantified by flow cytometry. A representative image of
flow cytometry using treated HL60 cells. The lower left quadrant represents live cells,
the lower right quadrant represents cells exhibiting early apoptosis and the upper right
quadrant represents late apoptotic cells.
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Table 4.1 Quantification of cells in each quadrant for each compound is shown in
Figure 4.10. Average of triplicate of each experiment was measured when the TIGK
cells were treated with the compounds. * indicates a significant increase (p<0.001) in late
apoptotic cells over medium and medium/DMSO controls.

Treatment

Conc (µM)

Late apoptosis/
Live cells (%) Early apoptosis (%) necrosis (%)

Medium

92.7

2.6

2.7

Medium/DMSO

91.3

1.4

3.9

Medium/H2O2

56.6

4.9

21.9*

N17

5
20
40

90.7
92.4
91.6

2.9
2.4
1.5

4.2
3.6
5.1

V8

5
20
40

91.6
92.8
92.8

3.1
2.1
2.4

4.2
3.5
3.4

N7

5
20
40

86.8
74.5
48.3

2.4
1.0
5.9

8.3
14.9*
40.7*
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Table 4.2: Quantification of early and late apoptotic J774A.1 cells treated with
compounds at different concentration. Average of triplicate of each experiment was
measured. * indicates a significant increase (p<0.001) in late apoptotic cells over medium
and medium/DMSO controls.

Treatment

Conc (µM)

Live cells (%) Early apoptosis (%)

Late apoptosis/
necrosis (%)

Medium

89.6

0.1

5.3

Medium/DMSO

89.6

0.9

5.6

Medium/H2O2

41.9

1.3

34.7*

5

87.8

1.0

6.1

20

85.3

1.0

6.9

40

87.3

1.2

6.6

5

85.1

1.1

8.3

20

83.4

0.9

8.0

40

84.3

12.5

9.1

2.5

5.5

N17

V8

N7

5

83.9

20

33.4

16.9*

46.6*

40

36.2

24.9*

38.0*
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Table 4.3: Quantification of early and late apoptotic HL60 cells treated with
compounds at different concentration. Average of triplicate of each experiment was
measured. * indicates a significant increase (p<0.001) in late apoptotic cells over medium
and medium/DMSO controls.

Treatment

Conc (µM)

Late apoptosis/
Live cells (%) Early apoptosis (%)
necrosis (%)

Medium

88.9

1.1

6.9

Medium/DMSO

90.0

1.2

6.6

52.7

12.3*

31.4*

Medium/H2O2
N17

5
20
40

91.3
90.3
91.6

2.7
2.2
2.3

4.7
6.0
6.3

V8

5
20
40

91.8
91.3
88.4

2.9
3.7
2.4

5.6
5.0
6.7

N7

5
20
40

87.4
27.3
18.9

3.6
20.9*
7.7

7.8
43.9*
70.8*
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Figure 4.11. Hemolytic assay: Hemolytic activity against sheep (A) and human (B) red
blood cells after 4 hr incubation with compounds N7, N17 and V8 at 5, 20, or 40 µM. ns,
not significant.
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4.3. Discussion
P. gingivalis may contribute to the initiation and progression of periodontitis by
functioning as a keystone pathogen that alters host innate immune functions leading to
dysbiosis and chronic inflammation

[41, 52, 152]. This raises the possibility that

therapeutic approaches that are specific for P. gingivalis may be effective in controlling
periodontal disease. One potential therapeutic target is the interaction of Mfa1 with
streptococcal AgI/II, which may contribute to the initial colonization of the oral cavity by
P. gingivalis.
Structural dissection of both AgI/II [134-136] and Mfa1 [168] previously identified
specific amino acids and motifs that are required for adherence of P. gingivalis with
streptococci and facilitated the development of a peptide that inhibits this interaction
[135]. However, P. gingivalis is a highly proteolytic organism, which would likely limit
the application of this peptide for therapeutic purposes. To address this limitation, small
molecule peptidomimetics have been recently synthesized and were shown to inhibit P.
gingivalis adherence [141, 142, 161]. In this study, we sought to identify additional small
molecule inhibitors by virtual screening of the ZINC database (https://zinc.docking.org/)
[148, 149, 169] for commercially available compounds that exhibit similarity with the
NITVK and VQDLL functional motifs of the streptococcal AgI/II protein. Three lead
compounds, N7, N17 and V8, were identified and shown to inhibit

P.

gingivalis/streptococcal adherence in vitro and to reduce P. gingivalis virulence in vivo.
Of the three compounds, N17 was the most potent inhibitor of P. gingivalis adherence in
vitro and exhibited an IC50 of ~18 µM, similar to the first generation peptidomimetic
compounds based on BAR peptide reported by Patil et al. [141] .
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Preliminary

experiments using equimolar mixtures of N17 and V8 did not indicate significant
synergistic activity.

One possible explanation for this is that the binding of one

compound, e.g., N17, to Mfa1 may sterically hinder the association of V8. In vivo, it has
been previously shown that the presence of S. gordonii in the murine oral cavity
promotes P. gingivalis virulence [135, 142] and consistent with this, infection of mice
with both S. gordonii and P. gingivalis induced inflammation leading to resorption of
alveolar bone. Treatment of infected animals with each of the compounds resulted in a
significant reduction in P. gingivalis-mediated inflammation and bone loss. Indeed, bone
loss in mice treated with compound N17 was not statistically different from shaminfected animals. Since compounds effectively reduce the adherence of P. gingivalis to S.
gordonii, P. gingivalis induced IL 17 expression also reduced in gingival tissue in
infected mice.
Compounds N17 and V8 exhibited little cytotoxicity against human gingival epithelial
cells or human and mouse macrophage cell lines. In contrast, N7 exhibited a significant
level of cytotoxicity in each of the cell culture tests that were performed. However, mice
that were treated with compound N7 during the infection process did not exhibit any
overt signs of distress or toxicity. This could be explained by the difference in the
duration of exposure to the compound in the in vitro versus in vivo experiments. Animals
that were treated with N7 were only transiently exposed (~20 min) to the compound
during infection with P. gingivalis whereas cell cultures were exposed to N7 for 18 hr
prior to the toxicity analyses.
One potential application that we envision for these compounds would be to prevent or
reduce colonization of the re-developing oral microbiome by P. gingivalis after a patient
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is treated for periodontitis. Typically, the oral microbiome re-forms after treatment and
disease recurrence can often occur. We speculate that topical application of these
compounds, formulated in a dental varnish or mouth rinse may direct the redevelopment of the microbial community towards a healthy rather than pathogenic
biofilm by preventing re-colonization of P. gingivalis. Our observation that transient
exposure of animals to the compounds significantly reduced P. gingivalis virulence
provides initial proof of concept that preventing P. gingivalis colonization of the oral
microbiome may result in positive clinical outcomes. In addition, we previously showed
that BAR peptide was also capable of disrupting an established biofilm containing P.
gingivalis [170], which suggests that N17 and V8 may also have utility in treating
existing periodontal infections.
In summary, virtual screening of the ZINC database identified three compounds that
inhibited P. gingivalis adherence to oral streptococci and represent potential targeted
therapeutics against periodontal disease. Two of these exhibited biocompatibility with
both human and mouse cells and represent lead compounds that will provide a platform
for further modification to improve potency.
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CHAPTER FIVE: SUMMARY
Periodontal disease is one of the most common oral diseases in the world and up to 47%
of the adult population in the United States suffer from this disease [18]. Managing these
diseases is also very expensive and each year, it costs $15 billion dollars. Moreover,
periodontitis is associated with systemic illness and increases the risk of heart disease,
rheumatoid arthritis, diabetes, renal failure and Alzheimer's disease [153, 171].
Porphyromonas gingivalis is strongly associated with chronic adult periodontitis and is
an important pathogen that is capable of modulating the host immune response and
disrupting normal host/microbe homeostasis [41, 52, 152]. This can lead to the
development of a dysbiotic microbial community which can induce uncontrolled
inflammation leading to the destruction of tooth-supporting tissues, and ultimately tooth
loss [42, 43].
The treatment of periodontal disease involves mechanical removal of dental plaque, a
combination of antibiotic therapy, surgical removal of infected tissue and tissue
regeneration therapy. The concern of antibiotic resistance and invasive treatment often
perturb the complex microbial community that requires to maintain healthy gum.
Targeted therapeutic approach against major pathogens associated with oral diseases
could be an interesting avenue to treat periodontal diseases. Identifying and targeting the
essential genes against pathogenic bacteria and blocking the gene function is one
approach for targeted therapy. For instance, Stone et al. identified meso-diaminopimelate
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dehydrogenase which catalyzes the formation of M-DAP (diaminopimelate), an
intermediate for lysine synthesis that is required for peptidoglycan synthesis as an
essential P. gingivalis gene and targeting the meso-diaminopimelate with small molecule
inhibitors effectively kills P. gingivalis cells [165]. Another attractive approach is the
delivery of naturally occurring antimicrobial peptides or synthetic peptides in the oral
cavity. For instance, Franzman et al. conjugated the P. gingivalis IgG with naturally
occurring sheep myeloid antimicrobial peptide (SMAP) that specifically kills P.
gingivalis in mixed-species biofilm [172]. Mahmoud et al. demonstrated that synthetic
BAR peptide released by nanoparticles reduced P. gingivalis biofilm formation and
prevented the loss of alveolar bone in an animal model of periodontitis [170, 173]. Thus,
targeting pathogenic biofilm formation represents a valid approach to develop targeted
therapies. Since P. gingivalis fimbriae mediate the physical interaction with other
organisms and host cells, downregulating the expression of fimbriae, inhibiting fimbrial
biogenesis, or targeting specific adhesin-receptor interactions are additional potential
approaches for therapy development. For instance, Ho et al. showed that peptides derived
from S. cristatus ArcA, designated as Streptococcal-derived anti-P. gingivalis peptide
(SAAP), reduced FimA and Mfa1 expression along with some other virulence genes in P.
gingivalis and reduced biofilm formation by this organism [174, 175].

Wright et al.

screened a small molecule library and identified compounds with 2-aminoimidazole or 2aminobenzimidazole moieties that downregulated FimA and Mfa1 expression and
inhibited biofilm formation of P. gingivalis with S. gordonii [176]. Alei et al. used a
synthetic peptide derived from the C terminal conserved domain of Mfa1 to block Mfa1
polymerization and inhibited biofilm formation of P. gingivalis with S. gordonii [162].
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P. gingivalis may initially colonize the oral cavity by adhering to streptococci and this
interaction not only facilitates P. gingivalis colonization of the oral cavity but increases
its virulence

[51, 70, 72, 127, 135]. Therefore, this interaction is an ideal point for

intervention. Adherence of P. gingivalis to streptococci is driven by two sets of adhesinreceptor interactions but the interaction of the short fimbrial protein Mfa1 of P. gingivalis
with streptococcal surface antigen AgI/II is crucial

[94, 127, 135].

Daep et al.

characterized the binding region of Ag I/II, designated as BAR, and showed that this
region is comprised of two distinct structural motifs, NITVK and VQDLL, which
resembled the eukaryotic nuclear receptor box protein-protein interaction domain [134,
136]. Subsequently targeting P. gingivalis adherence to streptococci, Daep et al. showed
that a synthetic peptide representing BAR significantly reduced P. gingivalis-mediated
bone loss in a mouse model of periodontitis [135]. More recently, Patil et al. synthesized
peptidomimetics based on the BAR peptide which were effective in preventing in vitro
community formation [141] and reduced bone loss in the in vivo model [142]. However,
no other therapeutic compounds currently exist that specifically target P. gingivalis and
inhibit its colonization of the oral cavity by preventing its association with oral
streptococci. To develop additional more potent therapeutic agents, characterization of
the Mfa1 binding site was required in order to better understand the mechanism of this
protein-protein interaction at the molecular level.
In this study, I successfully characterized and identified Mfa1 fimbrial residues involved
in interactions with AgI/II using peptide mapping, in silico docking and mutagenesis
approaches. From the peptide mapping studies (Figure 3.1), we showed that the
functional region of Mfa1 resides between residues 225-400 (Figure 3.2). Taking
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advantage of the Mfa1 3D structure [100] and peptidomimetics based on the BAR
peptide [141, 142], a putative binding cleft was predicted using Sitemap (Figure 3.3).
Integrating the findings from peptide mapping with this in silico prediction, R240, W275
and two amphipathic regions (residues 321–329 and 351–364) were targeted for sitedirected mutagenesis and these studies confirmed the predicted binding cleft by
demonstrating that these residues were essential for the interaction (Figure 3.4). Finally,
full length mfa1 genes containing mutations at R240 or A357 were constructed and
complemented in a P. gingivalis Mfa1 deficient strain and analyzed their ability to adhere
to S. gordonii (Figure 3.5b). The complemented strains were deficient in adherence, thus
further validating that these residues comprise part of the binding cleft involved in the
interaction with Ag I/II. To rule out the possibility that these mutations may influence the
secretion or polymerization of Mfa1 [89, 100-102], cell surface levels of Mfa1 and self
polymerization were examined. Neither mutation affected these events (Figure 3.5a and
3.6). Together, our findings suggest that R240, W275, amphipathic helical regions
(residues 321–329 and 351–364) are required for the interaction of Mfa1 with Ag I/II.
However, K70 and helical regions 180-194 were also predicted to comprise parts of the
binding cleft, so further studies will be required to determine the functional activity of
these amino acids in the interaction with Ag I/II.
To discover candidate drug-like compounds that target P. gingivalis adherence to the
streptococcal surface, a virtual screening was performed of commercially available
compounds contained in the ZINC databases [149, 169] to identify compounds with
structural similarity to the NITVK and VQDLL motifs of Ag I/II [146]. Three lead
compounds were identified that inhibit in vitro biofilm formation (Figure 4.1 and 4.2). In
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vivo effectiveness was also determined in mice by treating animals with compounds N7,
N17 or V8 at a concentration of 40 µM. Treatment significantly reduced alveolar bone
loss relative to untreated mice (Figure 4.5.). IC50 values for these compounds were
~15µM, similar to the first generation BAR peptidomimetics synthesized by Patil et al.
[141]. Thus, these compounds represent lead compounds that can be further modified to
increase their effectiveness similar to synthetic BAR peptide (IC50 1.3 µM) [134].
Furthermore, consistent with a previous study by Mahmoud et al. [173] that targeted the
interaction of Mfa1-Ag I/II using BAR peptide encapsulated nanoparticles, treatment
with N7, N17 or V8 reduced local IL-17 levels in the gingival tissues (Figure 4.6).
Finally, cytotoxic activity of the compounds was evaluated using various human and
murine cell lines by measuring levels of LDH release, cellular ATP, cell apoptosis and
hemolytic activity. N17 and V8 showed minimal detectable cytotoxic activity, whereas
compound N7 was toxic to the cells (Figure 4.8, 9, 10, 11, and Table 4.1, 4.2 and 4.3).
However, none of the compounds exhibited toxic activity in the in vivo experiments. An
explanation for this may be that mice were only transiently exposed to the compounds
during the infection process whereas the cell lines were chronically exposed for 24 hours
prior to determining in vitro cytotoxicity.

Thus, N17 and V8 represent potential

therapeutic agents that may be useful in the treatment or prevention of periodontal
diseases. We also recognize that the microbial community in the oral cavity is complex.
For example, F. nucleatum is often co-local with P. gingivalis and co-infection with both
organisms has been associated with increased virulence [177, 178], so further studies will
be required to determine the efficacy of the candidate compounds in more complex
biofilm model.
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In brief, I successfully identified the binding residues of Mfa1 that interact with Ag I/II
surface antigen and also identified small molecule inhibitors that are effective in reducing
P. gingivalis virulence. Overall, the valuable insight of this protein-protein interaction
will facilitate the structural modification of the lead compounds in order to design more
potent inhibitors that will reduce P. gingivalis colonization and virulence in the oral
cavity. It would also be interesting to determine the efficacy of these inhibitors in clinical
studies. For example, a Specifically Targeted Antimicrobial Peptide (STAMPs) was
developed (designated C16G2) against the cariogenic pathogen S. mutans that is
comprised of 16mer S. mutans competence stimulating peptide (CSP) linked to the broad
spectrum antimicrobial peptide G2. This STAMP potently killed S. mutans in a mixedspecies community without perturbing the commensal organisms [179, 180]. C16G2 has
been formulated in a dental varnish and dental strip and is currently undergoing a Phase 2
clinical trial. Thus, we could hypothesize that formulation of the small molecule
inhibitors identified in this study might be effective in a mouth rinse, dental varnish or
dental strip to specifically eliminate P. gingivalis.

A potential limitation of these

formulations however, is that they would only transiently deliver the active agent to the
oral cavity. Recent studies have examined the use of nanoparticles and nanofibers to
increase the concentration and duration of active agents for oral applications [170, 173,
181]. Indeed, nanoparticles have been widely used for the delivery of preventive drugs,
in tooth implantation approaches and for the treatment of oral cancer [182]. We envision
the possibility of delivering the small molecule inhibitors using nanoparticles and that
nanoparticles-inhibitor conjugates could be formulated in a rinse, varnish or strip to
improve the performance of these formulations.
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Mfa1

X

Colonization and
virulence of P.
gingivalis in the oral
cavity

SspA/B

Figure 5. Graphical summary: The Minor fimbriae of P. gingivalis 3D structure
was solved by Hall et al. (2018). Here we identified the binding antigens of Mfa1 that
interact with Ag I/II depicted in rainbow color. Based on NITVK (cyan) and VQDLL
(green) motif of SspA/B, lead compounds were identified that reduce P. gingivalis
colonization and virulence in animal model of periodontitis.
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CHAPTER SIX: FUTURE DIRECTIONS
6.1. Co-crystallization of Mfa1 with BAR peptide/peptidomimetics: R240, W275, and
the amphipathic regions (residues 321-326, 351-364) were identified as crucial amino
acids of the Mfa1 binding cleft, but residue K70 and a putative helical region (residues
180-194) were also predicted as binding cleft residues. Their role in the interaction with
Ag I/II needs to be further characterized to better understand the mechanism of this
protein-protein interaction. Since the Mfa1 3D structure was recently published [100], it
may be possible to co-crystallize Mfa1-BAR peptide or to the Mfa1-peptidomimetics
(synthesized by Patil et.al.[141, 161]) to obtain a more complete picture of the binding
interface as well as understanding the mechanism of this protein-protein interaction. To
achieve this goal, purified Mfa1 can be conjugated with an equimolar concentration of
BAR or ligands, and X-ray crystallography can be performed.
6.2. Determine the efficacy of the lead compounds in the presence of bridging
organism: The dental biofilm is a complex and organized microbial structure where
other microorganisms such as Fusobacterium nucleatum independently interact with P.
gingivalis and oral streptococci [50, 183]. So to be considered as functional therapeutic
agents, it will be necessary to determine the efficacy of the lead compounds in dispersing
P. gingivalis-streptococcal biofilms in the presence of such organisms.

Tan et al.

developed a three species biofilm model by introducing the bridging organism F.
nucleatum in dual-species biofilm [142] and have tested the efficacy of peptidomimetic
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compounds on the dispersion of this mixed-species biofilm. Fortunately, Tan et al. found
peptidomimetics effectively inhibit biofilm formation in this three species biofilm model
and have also shown these compounds effectively disperse a preformed biofilms [142].
Thus, it is possible to test the efficacy of the lead compounds in inhibition in the three
species biofilm model. It will also be interesting to determine the effectiveness of these
compounds in the dispersion of preformed dual-species or three species biofilms.
6.3. Determination the effectiveness of the lead compounds in combined treatment:
NITVK and VQDLL of Ag I/II were identified as crucial for interaction with Mfa1 [134,
136]. Patil et al. [141, 157] synthesized peptidomimetics using a click chemistry
approach, taking into consideration both of these motifs which effectively prevent biofilm
formation. The lead compounds, N17 and V8 are based on the NITVK and VQDLL
motifs respectively, and reduce bone loss in mice model of periodontitis but less
effectively than BAR peptide (IC50 = 1.3µM) [135]. One possibility is that treatment
with a mixture of both N17 and V8 may increase effectiveness since mimics of both
motifs will be present. Our preliminary findings (data not shown) suggest that when
mice were treated with a combination of these two compounds (each at 5 µM)
significantly reduced bone loss in the mice model. However, further studies will be
required to determine the effectiveness of these compound mixtures at lower
concentrations.
6.4. Structure-Activity Relationship (SAR) Study of the Lead compounds: SAR is a
powerful tool to refine and improve the potency of active compounds by changing their
chemical structure and subsequently assessing their functionality. SAR study can be
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performed using the free tools “Chembench” (https://chembench.mml.unc.edu/)
developed by Tropsha Lab at the University of North Carolina at Chapel Hill [184].
6.5. Developing drug delivery vehicles: As discussed in Chapter 5, another challenge of
treating periodontal disease is the localized delivery of the active therapeutic agents in the
oral cavity because the systemic administration of drugs is ineffective against biofilm in
the deeper tissue area. Previous studies suggest that peptide modified nanoparticles
effectively disperse a preformed biofilm between P. gingivalis and oral streptococci
[170], and reduced P. gingivalis virulence in the mouse model of periodontitis [173].
Therefore, in collaboration with the Bioengineering Department, it may be possible to
develop poly lactic-co-glycolic acid (PLGA) nanoparticles that are surface-modified or
that encapsulate the candidate small molecule inhibitors as described by Steinbach et al.
[185] and assess their efficacy in dispersing a preformed biofilm dispersion in vitro as
well as in vivo efficacy in the animal model system. Some of the advantages of using the
PLGA are that it is already FDA approved, widely used as a food additive, relatively safe
to humans, easy to synthesize and has inherent antimicrobial effects. The goal will be to
engineering nanoparticle with our potential drug-like compounds to generate a platform
to effectively deliver the therapeutic agents in the oral cavity.
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